EP1944312B1 - Peptides qui lient spécifiquement le récepteur HGF (CMET) et utilisations associées - Google Patents

Peptides qui lient spécifiquement le récepteur HGF (CMET) et utilisations associées Download PDF

Info

Publication number
EP1944312B1
EP1944312B1 EP08008144A EP08008144A EP1944312B1 EP 1944312 B1 EP1944312 B1 EP 1944312B1 EP 08008144 A EP08008144 A EP 08008144A EP 08008144 A EP08008144 A EP 08008144A EP 1944312 B1 EP1944312 B1 EP 1944312B1
Authority
EP
European Patent Office
Prior art keywords
cmet
binding
peptide
polypeptide
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP08008144A
Other languages
German (de)
English (en)
Other versions
EP1944312A1 (fr
Inventor
Aaron K. Sato
Daniel T. Dransfield
Robert C. Ladner
Palaniappa Nanjappan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bracco Suisse SA
Dyax Corp
Original Assignee
Bracco Suisse SA
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco Suisse SA, Dyax Corp filed Critical Bracco Suisse SA
Priority to DK10185426.3T priority Critical patent/DK2284180T3/en
Priority to EP10185426.3A priority patent/EP2284180B1/fr
Priority to PL15157779T priority patent/PL2949658T3/pl
Priority to PL08008144T priority patent/PL1944312T3/pl
Priority to EP15157779.8A priority patent/EP2949658B1/fr
Publication of EP1944312A1 publication Critical patent/EP1944312A1/fr
Application granted granted Critical
Publication of EP1944312B1 publication Critical patent/EP1944312B1/fr
Priority to CY181100929T priority patent/CY1120683T1/el
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Definitions

  • Hepatocyte growth factor (also known as scatter factor) is a multi-functional growth factor involved in various physiological processes such as embryogenesis, wound healing and angiogenesis. It has become apparent that HGF, through interactions with its high affinity receptor (cMet), is involved in tumor growth, invasion and metastasis. In fact, dysregulated cMet expression (for example, the overexpression of cMet in neoplastic epithelium of colorectal adenomas and in other carcinomas as compared to normal mucosa) and/or activity, as well as hyperactivity of the cMet receptor through an autocrine stimulatory loop with HGF, has been demonstrated in a variety of tumor tissues and induces oncogenic transformation of specific cell lines.
  • cMet high affinity receptor
  • HGF is produced by the stromal cells, which form part of many epithelial tumors; however, it is believed that the production of HGF by tumor cells themselves comprises the main pathway leading to the hyperproliferation of specific tumors.
  • HGF/cMet autocrine stimulatory loops have been detected in gliomas, osteosarcomas, and mammary, prostate, breast, lung and other carcinomas.
  • HGF Interrupting the HGF interaction with the cMet receptor slows tumor progression in animal models.
  • HGF In addition to stimulating proliferation of certain cancer cells through activation of cMet, HGF also protects against DNA-damaging agent-induced cytotoxicity in a variety of cell lines susceptible to hyperproliferative phenotypes (e.g ., breast cancer). Therefore, preventing HGF from binding to cMet could predispose certain cancer cells to the cytotoxicity of certain drugs.
  • cMet In addition to hyperproliferative disorders, cMet also has been linked to angiogenesis. For example, stimulation of cMet leads to the production of vascular endothelial growth factor (VEGF), which, in turn, stimulates angiogenesis. Additionally, stimulation of cMet also has been implicated in promoting wound healing.
  • VEGF vascular endothelial growth factor
  • cMet receptor As a therapeutic target for hyperproliferative disorders, angiogenesis and wound healing, the large discrepancy between expression levels of neoplastic and corresponding normal tissues indicates that cMet is an attractive target for imaging applications directed to hyperproliferative disorders.
  • the present invention relates to peptides, peptide complexes and compositions having the ability to bind to cMet and antagonize hepatocyte growth factor (HGF) activity by preventing HGF from binding to cMet.
  • this invention relates to such peptides, peptide complexes and compositions having the ability to bind to cMet for the purpose of detecting and targeting this receptor, inhibiting cMet activity independent of HGF antagonistic properties.
  • HGF/cMet axis The involvement of the HGF/cMet axis in a variety of cellular functions including cellular proliferation, wound healing and angiogenesis, leading to hyperproliferative diseases such as cancer, make the present invention particularly useful for interrupting HGF-mediated physiological events, for targeting substances, e.g ., therapeutics, including radiotherapeutics, to such sites.
  • non-naturally occurring polypeptides as claimed in claim 1 bind specifically to cMet.
  • Conjugation or fusion of such polypeptides with effective agents such as cMet inhibitors or tumoricidal agents also can be used to treat pathogenic tumors, e.g ., by causing the conjugate or fusion to "home" to the site of active proliferation and/or angiogenesis, thereby providing an effective means for treating pathogenic conditions associated with hyperproliferation and/or angiogenesis.
  • This invention pertains to cMet binding polypeptides, and includes use of a single binding polypeptide as a monomer or in a multimeric construct as well as use of more than one binding polypeptide of the invention in multimeric constructs.
  • Binding polypeptides according to this invention are useful in any application where binding, inhibiting or isolating cMet, is advantageous.
  • a particularly important aspect of such binding polypeptides is the inhibition of cMet activity, either through competition with HGF for cMet binding, or by directly inhibiting cMet activity irrespective of whether HGF is bound or not.
  • cMet signaling can occur in the absence of HGF binding, in such situations, a binding polypeptide that inhibits cMet signaling activity irrespective of whether HGF is bound, would be useful in inhibiting cMet signaling.
  • binding polypeptides disclosed herein is in a method of imaging cellular proliferation and/or angiogenesis in vivo.
  • the method entails the use of specific binding polypeptides according to the invention for detecting a site of cellular proliferation and/or angiogenesis, where the binding polypeptides have been detectably labeled for use as imaging agents, including magnetic resonance imaging (MRI) contrast agents, x-ray imaging agents, radiopharmaceutical imaging agents, ultrasound imaging agents, and optical imaging agents.
  • imaging agents including magnetic resonance imaging (MRI) contrast agents, x-ray imaging agents, radiopharmaceutical imaging agents, ultrasound imaging agents, and optical imaging agents.
  • cMet binding polypeptides disclosed herein are to target therapeutic agents, (including compounds capable of providing a therapeutic, radiotherapeutic or cytotoxic effect) or delivery vehicles for therapeutics (including drugs, genetic material, etc.) to sites of hyperproliferation and/or angiogenesis or other tissue expressing cMet.
  • therapeutic agents including compounds capable of providing a therapeutic, radiotherapeutic or cytotoxic effect
  • delivery vehicles for therapeutics including drugs, genetic material, etc.
  • the cMet receptor is part of the receptor tyrosine kinase family of signaling molecules.
  • receptor tyrosine kinase function can include any one of: oligomerization of the receptor, receptor phosphorylation, kinase activity of the receptor, recruitment of downstream signaling molecules, induction of genes, induction of cell proliferation, induction of cell migration, or combination thereof.
  • heteromeric constructs of binding polypeptides provided herein could, for example, bind, via one binding peptide, to, for example, the HGF binding site of cMet, while another binding peptide of the heteromeric molecule binds to a different high affinity binding site of cMet.
  • Targeting two or more distinct epitopes on cMet with a single binding construct can greatly improve the ability of the construct to inhibit HGF binding and/or receptor function (such inhibition can occur by direct inhibition of cMet irrespective of HGF binding).
  • Even binding peptides with weak ability to block receptor activity can be used to generate heteromeric constructs having improved ability to block HGF-dependent and HGF-independent receptor function.
  • the present invention is drawn to constructs comprising means for producing multimeric molecules comprising two or more binding polypeptides, at least one of which binds cMet.
  • the multimeric constructs comprise two or more copies of a single binding polypeptide or nucleotide sequence that encode two or more copies of a single binding polypeptide.
  • the multimeric constructs of the present invention comprise two or more binding polypeptides or nucleotide sequence that encode two or more binding polypeptides, such that at least two of the binding polypeptides in the construct are specific for different epitopes of cMet.
  • These constructs also are referred to herein as "heteromeric constructs", “heteromultimers”, etc.
  • the constructs of the present invention also can include unrelated, or control peptide.
  • the constructs can include two or more, three or more, or four or more binding polypeptides or the nucleotide sequences that encode such polypeptides. Based on the teachings provided herein, one of ordinary skill in the art is able to assemble the binding polypeptides provided herein into multimeric constructs and to select multimeric constructs having improved properties, such as improved ability to bind the target molecule, or improved ability to inhibit receptor tyrosine kinase function. Such multimeric constructs having improved properties are included in the present invention.
  • Consensus sequences from the screen of the cyclic/linear peptide libraries have been determined based on the twelve classes of specific cMet binding polypeptides shown in Table 6.
  • the cMet binding polypeptides of the invention comprise one or more of the sequences according to SEQ ID No. 1.
  • Such preferred cMet binding polypeptides include polypeptides with the potential to form a cyclic or loop structure between invariant cysteine residues comprising.
  • binding polypeptides according to the invention can be prepared having N-terminal and/or C-terminal flanking peptides of one or more, preferably two, amino acids corresponding to the flanking peptides of the display construct of the phage selectant from which the binding polypeptides were isolated.
  • sequence information and binding data from the isolates of libraries containing polypeptides with the potential to form loop structures e.g ., libraries designated TN6, TN8, TN9, TN10, TN11 and TN12; the number refers to the number of amino acids in the sequence from cysteine to cysteine; additionally, the linear display library, LN20, also was screened) identifies an additional series of cMet binding polypeptides.
  • cMet binding polypeptides or multimeric polypeptide construct of the invention can be used as therapeutic agents, either alone in a pharmaceutically acceptable composition or conjugated to (or in combination with) other therapeutic agents.
  • the compositions can be used to treat diseases or conditions involving cellular proliferation, angiogenesis and/or wound healing.
  • the peptides When used as therapeutic agents, it may be advantageous to enhance the serum residence time of the peptides. This can be accomplished by: a) conjugating to the peptide a moiety, such as maleimide, that reacts with free sulfhydryl groups on serum proteins, such as serum albumin, b) conjugating to the peptide a moiety, such as a fatty acid, that binds non-covalently to serum proteins, especially serum albumin, c) conjugating to the peptide a polymer, such as polyethylene glycol (PEG), that is known to enhance serum residence time, and d) fusing DNA that encodes the cMet-binding peptide to DNA that encodes a serum protein such as human serum albumin or an antibody and expressing the encoded fusion protein.
  • a moiety such as maleimide
  • the peptide a moiety such as a fatty acid
  • PEG polyethylene glycol
  • the present invention is directed to a polypeptide or multimeric polypeptide construct having the ability to bind to cMet or a complex comprising cMet and HGF comprising an amino acid sequence as claimed in claim 1 in a particular embodiment, the polypeptide, used as either a monomer or in a multimeric construct, can be selected from the group consisting of SEQ ID NOS: 6 to 13.
  • herein described is a method of treating a condition involving activation ofcMet, comprising administering to an animal or human subject in need of treatment for such a condition a composition comprising a polypeptide or multimeric polypeptide construct having the ability to bind to cMet or a complex comprising cMet and HGF comprising an amino acid sequence as claimed in claim 1.
  • herein described is a method of treating a condition involving activation of cMet, comprising administering to an animal or human subject in need of treatment for such a condition a composition comprising a polypeptide or multimeric polypeptide construct having the ability to bind to cMet or a complex comprising cMet and HGF comprising an amino acid sequence, wherein the amino acid sequence comprises a contiguous stretch of amino acids from a sequence selected from the group consisting of SEQ ID NOS: 6 to 13.
  • the condition is solid tumor growth, e.g ., wherein the tumor is selected from the group consisting of breast, thyroid, glioblastoma, prostate, malignant mesothelioma, colorectal, hepatocellular, hepatobiliary, renal, osteosarcoma and cervical.
  • the polypeptide or multimeric polypeptide construct can be conjugated to a tumoricidal agent.
  • a recombinant bacteriophage displaying any one or more of the polypeptides or multimeric polypeptide construct described herein or having any one or more of the consensus sequences described herein, such that the phage has the ability to bind to cMet or a complex comprising cMet and HGF, and wherein the polypeptide is displayed on the surface of the recombinant bacteriophage.
  • the present invention provides novel binding moieties that bind to the hepatocyte growth factor receptor ("HGFr” or "cMet").
  • HGFr hepatocyte growth factor receptor
  • cMet hepatocyte growth factor receptor
  • the binding polypeptides and multimeric polypeptide constructs of the invention can be used to form a variety of therapeutic agents for-treating neoplastic tumor growth or other proliferative disorders.
  • the binding polypeptides and multimeric polypeptide constructs can themselves be used as therapeutic agents.
  • cMet binding polypeptides were isolated initially by screening of phage display libraries, that is, populations of recombinant bacteriophage transformed to express an exogenous peptide on their surface.
  • phage display libraries that is, populations of recombinant bacteriophage transformed to express an exogenous peptide on their surface.
  • screening of large peptide libraries for example using phage display techniques, is especially advantageous, in that very large numbers ( e.g ., 5 ⁇ 10 9 ) of potential binders can be tested and successful binders isolated in a short period of time.
  • a candidate binding domain is selected to serve as a structural template for the peptides to be displayed in the library.
  • the phage library is made up of a multiplicity of analogues of the parental domain or template.
  • the binding domain template can be a naturally occurring or synthetic protein, or a region or domain of a protein.
  • the binding domain template can be selected based on knowledge of a known interaction between the binding domain template and the binding target, but this is not critical.
  • the selected domain it is not essential for the selected domain to act as a template for the library or have any affinity for the target at all; its purpose is to provide a structure from which a multiplicity (library) of similarly structured polypeptides (analogues) can be generated, which multiplicity of analogs will include one or more analogs that exhibit the desired binding properties (and any other properties screened for).
  • the analogs are generated by insertion of synthetic DNA encoding the analogs into phage, resulting in display of the analog on the surfaces of the phage.
  • Such libraries of phage such as M13 phage, displaying a wide variety of different polypeptides, can be prepared using techniques as described, e.g ., in Kay et al., Phage Display of Peptides and Proteins: A Laboratory Manual (Academic Press, Inc., San Diego, 1996 ) and US 5,223,409 (Ladner et al .).
  • TN6, TN7, TN8, TN9, TN10, TN11, TN12, and a linear library, designated LN20 were initially screened.
  • Each library was constructed for expression of diversified polypeptides on M13 phage.
  • the seven libraries having a "TN” designation were designed to display a short, variegated exogenous peptide loop of 6, 7, 8, 9, 10,11 or 12 amino acids, respectively, on the surface of M13 phage, at the amino terminus of protein III.
  • the libraries are designated TN6 (having a potential 3.3 ⁇ 10 12 amino acid sequence diversity), TN7 (having a potential 1.2 ⁇ 10 14 amino acid sequence diversity), TN8 (having a potential 2.2 ⁇ 10 15 amino acid sequence diversity), TN9 (having a potential 4.2 ⁇ 10 16 amino acid sequence diversity, TN10 (having a potential 3.0 ⁇ 10 16 amino acid sequence diversity), TN11 (having a potential 1.5 ⁇ 10 19 amino acid sequence diversity), TN12 (having a sequence diversity of 4.6 ⁇ 10 19 ), and LN20 (having a potential 3.8 ⁇ 10 25 amino acid sequence diversity).
  • the TN6 library was constructed to display a single microprotein binding loop contained in a 12-amino acid template.
  • the TN6 library utilized a template sequence of Xaa1 - Xaa2 - Xaa3 - Cys - Xaa5 - Xaa6 - Xaa7 - Xaa8 - Cys - Xaa10 - Xaa11 - Xaa12.
  • the amino acids at positions 2, 3, 5, 6, 7, 8,10, and 11 of the template were varied to permit any amino acid except cysteine (Cys).
  • the amino acids at positions 1 and 12 of the template were varied to permit any amino acid except cysteine (Cys), glutamic acid (Glu), isoleucine (Ile), Lysine (Lys), methionine (Met), and threonine (Thr).
  • the TN7 library was constructed to display a single microprotein binding loop contained in a 13-amino acid template.
  • the TN7 library utilized a template sequence of Xaa1 - Xaa2 - Xaa3 - Cys - Xaa5 - Xaa6 - Xaa7 - Xaa8 - Xaa9 - Cys - Xaa1 Xaa12 - Xaa13.
  • the amino acids at amino acid positions 1, 2, 3, 5, 6, 7, 8, 9, 11, 12, and 13 of the template were varied to permit any amino acid except cysteine (Cys).
  • the TN8 library was constructed to display a single microprotein binding loop contained in a 14-amino acid template.
  • the TN8 library utilized a template sequence of Xaa1 - Xaa2 - Xaa3 - Cys - Xaa5 - Xaa6 - Xaa7 - Xaa8 - Xaa9 - Xaa10 - Cys - Xaa12 - Xaa 13 - Xaa 14.
  • the amino acids at position 1, 2, 3, 5, 6, 7, 8, 9, 10, 12, 13, and 14 in the template were varied to permit any amino acid except cysteine (Cys).
  • the TN9 library was constructed to display a single microprotein binding loop contained in a 15-amino acid template.
  • the TN9 library utilized a template sequence Xaa1 - Xaa2 - Xaa3 - Cys - Xaa5 - Xaa6 - Xaa7 - Xaa8 - Xaa9 - Xaa10 - Xaa11 - Cys - Xaa13 - Xaa14 - Xaa 15.
  • the amino acids at position 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 13, 14 and 15 in the template were varied to permit any amino acid except cysteine (Cys).
  • the TN10 library was constructed to display a single microprotein binding loop contained in a 16-amino acid template.
  • the TN10 library utilized a template sequence Xaa1- Xaa2 - Xaa3 - Cys - Xaa5 - Xaa6 - Xaa7 - Xaa8 - Xaa9 - Xaa10 - Xaa11 - Xaa12 - Cys - Xaa14 - Xaa15 - Xaa16.
  • the amino acids at positions 1, 2, 15, and 16 in the template were varied to permit any amino acid selected from a group of 10 amino acids: D, F, H, L, N, P, R, S, W, or Y).
  • the amino acids at positions 3 and 14 in the template were varied to permit any amino acid selected from a group of 14 amino acids: A, D, F, G, H, L, N, P, Q, R, S, V, W, or Y).
  • the amino acids at positions 5, 6, 7, 8, 9, 10, 11, and 12 in the template were varied to permit any amino acid except cysteine (Cys).
  • the TN11 library was constructed to display a single microprotein binding loop contained in a 17-amino acid template.
  • the TN11 library utilized a template sequence Xaa1 -Xaa2 - Xaa3 - Cys - Xaa5 - Xaa6 - Xaa7 - Xaa8 - Xaa9 - Xaa10 Xaa11 - Xaa12 - Xaa13-Cys -Xaa15- Xaa16-Xaa17.
  • the amino acids at positions 1 through 3, 5 through 13, and 15 through 17 in the template were varied to permit any amino acid except cysteine (Cys).
  • the TN12 library was constructed to display a single microprotein binding loop contained in an 18-amino acid template.
  • the TN12 library utilized a template sequence Xaa1- Xaa2 - Xaa3 - Cys - Xaa5 - Xaa6 - Xaa7 - Xaa8 - Xaa9 - Xaa10 Xaa11- Xaa12 - Xaa13 - Xaa14 - Cys-Xaa16 - Xaa17 - Xaa18.
  • amino acids at position 1, 2, 17, and 18 in the template were varied to permit any amino acid selected from a group of 12 amino acids: A, D, F, G, H, L, N, P, R, S, W, or Y).
  • amino acids at positions 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, and 16 were varied to permit any amino acid except cysteine (Cys).
  • the LN20 library was constructed to display multiple linear peptides on the surface of a phage. Each phage, however, displays multiple copies of the same sequence. Therefore, a single phage will display, for example, five copies of a particular sequence, a different phage will display, for example, five copies of a different sequence, etc.
  • the linear peptides are provided in a 20-amino acid template. The amino acids at each position in the template were varied to permit any amino acid except cysteine (Cys).
  • binding polypeptides provided herein can include additions in the N- and/or C- termini. Such modified binding polypeptides are expected to bind cMet. Binding polypeptides comprising the loop portion of the templates and sequences provided herein are expected to bind cMet and also are encompassed by the present invention.
  • the loop portion of the templates and sequences includes the sequences between and including the two cysteine residues that are expected to form a disulfide bond, thereby generating a peptide loop structure.
  • the binding polypeptides of the present invention can include additional amino acid residues at the - and/or C-termini.
  • the phage display libraries were created by making a designed series of mutations or variations within a coding sequence for the polypeptide template, each mutant sequence encoding a peptide analog corresponding in overall structure to the template except having one or more amino acid variations in the sequence of the template.
  • the novel variegated (mutated) DNA provides sequence diversity, and each transformant phage displays one variant of the initial template amino acid sequence encoded by the DNA, leading to a phage population (library) displaying a vast number of different but structurally related amino acid sequences.
  • the amino acid variations are expected to alter the binding properties of the binding peptide or domain without significantly altering its structure, at least for most substitutions.
  • amino acid positions that are selected for variation will be surface amino acid positions, that is, positions in the amino acid sequence of the domains that, when the domain is in its most stable conformation, appear on the outer surface of the domain ( i.e ., the surface exposed to solution).
  • amino acid positions to be varied will be adjacent or close together, so as to maximize the effect of substitutions.
  • a phage library is contacted with and allowed to bind the target, or a particular subcomponent thereof.
  • Phage bearing a target-binding moiety form a complex with the target on the solid support whereas non-binding phage remain in solution and can be washed away with excess buffer.
  • Bound phage are then liberated from the target by changing the buffer to an extreme pH (pH 2 or pH 10), changing the ionic strength of the buffer, adding denaturants, or other known means.
  • a protein elution is performed, i.e., some phage are eluted from the target using HGF in solution (competitive elution). Additionally, for example, very high affinity binding phage that could not be competed off during the overnight HGF incubation were captured by using the phage still bound to substrate for infection of E. coli cells.
  • the recovered phage can then be amplified through infection of bacterial cells and the screening process can be repeated with the new pool that is now depleted in non-binders and enriched for binders.
  • the recovery of even a few binding phage is sufficient to carry the process to completion.
  • the gene sequences encoding the binding moieties derived from selected phage clones in the binding pool are determined by conventional methods, described below, revealing the peptide sequence that imparts binding affinity of the phage to the target.
  • the sequence diversity of the population falls with each round of selection until desirable binders remain.
  • the sequences converge on a small number of related binders, typically 10-50 out of about 10 9 to 10 10 original candidates from each library.
  • the sequence information can be used to design other secondary phage libraries, biased for members having additional desired properties. Formation of the disulfide binding loop is advantageous because it leads to increased affinity and specificity for such peptides.
  • the disulfide bond can be opened by free cysteines or other thiol-containing molecules. Thus, it could be useful to modify the cysteine residues to replace the disulfide cross-link with another less reactive linkage.
  • the -CH 2 -S-S-CH 2 -cross-link has a preferred geometry in which the dihedral bond between sulfurs is close to 90 degrees, but the exact geometry is determined by the context of other side groups and the binding state of the molecule. Preferred modifications of the closing cross-link of the binding loop will preserve the overall bond lengths and angles as much as possible.
  • Direct synthesis of the polypeptides of the invention can be accomplished using conventional techniques, including solid-phase peptide synthesis, solution-phase synthesis, etc. Solid-phase synthesis is preferred (see, for example, Stewart et al., Solid-Phase Peptide Synthesis (W. H. Freeman Co., San Francisco, 1989 ); Merrifield, J., 1963, Am. Chem. Soc., 85:2149-2154 ; Bodanszky and Bodanszky, The Practice of Peptide Synthesis (Springer-Verlag, New York, 1984 )).
  • Polypeptides according to the invention can also be prepared commercially by companies providing peptide synthesis as a service (e.g ., BACHEM Bioscience, Inc., King of Prussia, PA; Quality Controlled Biochemicals, Inc., Hopkinton, MA).
  • the polypeptide compound is preferably purified after it has been isolated or synthesized by either chemical or recombinant techniques.
  • purification purposes there are many standard methods that may be employed, including reversed-phase high pressure liquid chromatography (RP-HPLC) using an alkylated silica column such as C 4 -, C 8 - or C 18 -silica.
  • RP-HPLC reversed-phase high pressure liquid chromatography
  • a gradient mobile phase of increasing organic content is generally used to achieve purification, for example, acetonitrile in an aqueous buffer, usually containing a small amount of trifluoroacetic acid.
  • Ionexchange chromatography can also be used to separate peptides based on their charge.
  • the degree of purity of the polypeptide can be determined by various methods, including identification of a major large peak on HPLC.
  • a polypeptide that produces a single peak that is at least 95% of the input material on an HPLC column is preferred. Even more preferable is a polypeptide that produces a single peak that is at least 97%, at least 98%, at least 99% or even 99.5% or more of the input material on an HPLC column.
  • composition analysis can be carried out.
  • Such composition analysis can be conducted using high resolution mass spectrometry to determine the molecular weight of the peptide.
  • the amino acid content of the peptide can be confirmed by hydrolyzing the peptide in aqueous acid, and separating, identifying and quantifying the components of the mixture using HPLC, or an amino acid analyzer. Protein sequenators, which sequentially degrade the peptide and identify the amino acids in order, can also be used to determine the sequence of the peptide.
  • cMet binding polypeptides according to the present invention also can be produced using recombinant DNA techniques, utilizing nucleic acids (polynucleotides) encoding the polypeptides according to this invention and then expressing them recombinantly, i.e ., by manipulating host cells by introduction of exogenous nucleic acid molecules in known ways to cause such host cells to produce the desired cMet binding polypeptides.
  • nucleic acids polynucleotides
  • a determination of the affinity of the cMet binding moiety for cMet relative to another protein or target is a useful measure, and is referred to as specificity for cMet.
  • Standard assays for quantitating binding and determining affinity include equilibrium dialysis, equilibrium binding, gel filtration, or the monitoring of numerous spectroscopic changes (such as a change in fluorescence polarization) that result from the interaction of the binding moiety and its target. These techniques measure the concentration of bound and free ligand as a function of ligand (or protein) concentration.
  • a solution of the data to this equation yields the association constant, K a , a quantitative measure of the binding affinity.
  • the association constant, K a is the reciprocal of the dissociation constant, K D .
  • the K D is more frequently reported in measurements of affinity.
  • cMet binding polypeptides can have a K D for cMet in the range of, for example, less than 1 nanomolar (nM), I nM to 100 micromolar ( ⁇ M), which includes K D values of less than 10 nM, less than 20 nM, less than 40 nM, less than 60 nM, less than 80 nM, less than 1 ⁇ M, less than 5 ⁇ M, less than 10 ⁇ M, less than 20 ⁇ M, less than 40 ⁇ M, less than 60 ⁇ M, and less than 80 ⁇ M.
  • Quantitative measurement of dissociation rates can be performed using several methods known in the art, such as fiber optic fluorimetry (see, for example, Anderson and Miller, 1988, Clin. Chem., 34:1417-21 ), surface plasmon resonance (see, for example, Malmborg et al., 1996, J. Immunol. Methods, 198:51-7 ; and Schuck, 1997, Curr. Op. Biotechnol., 8:498-502 ), resonant mirror, and grating coupled planar waveguiding (see, for example, Hutchinson, 1995, Molec. Biotechnol., 3:47-54 ).
  • fiber optic fluorimetry see, for example, Anderson and Miller, 1988, Clin. Chem., 34:1417-21
  • surface plasmon resonance see, for example, Malmborg et al., 1996, J. Immunol. Methods, 198:51-7 ; and Schuck, 1997, Curr. Op. Biotechnol., 8:498-502
  • BIAcore surface plasmon resonance sensor Biacore AB, Uppsala SE
  • IAsys resonant mirror sensor Fiber Applied Sensor Technology, Cambridge GB
  • BIOS-1 grated coupled planar waveguiding sensor Articleificial Sensor Instruments, Zurich CH.
  • polypeptide sequences in the dimeric constructs can be attached at their N- or C- terminus or the N-epsilon nitrogen of a suitably placed lysine moiety (or another function bearing a selectively derivatizable group such as a pendant oxyamino or other nucleophilic group), or can be joined together via one or more linkers ( e.g ., those discussed herein) employing the appropriate attachment chemistry.
  • This coupling chemistry can include amide, urea, thiourea, oxime, or aminoacetylamide (from chloro- or bromoacetamide derivatives, but is not so limited).
  • methods to prepare dimeric or multimeric constructs of cMet binding polypeptides of the invention include at least those discussed below.
  • cMet-binding peptides can be built up on Ellman-type safety catch resin using automated or manual Fmoc peptide synthesis protocols ( Backes et al., 1996. J. Am. Chem. Soc., 118:3055-56 ).
  • a di-lysine derivative can be constructed on 2-chlorotrityl resin ( Fields et al., "Principles and Practice of Solid Phase Synthesis" in Synthetic Peptides, A Users Guide, Grant, Ed. (W.H. Freeman Co., New York, 1992), Ch. 3, pp.
  • the prior-mentioned safety-catch resin is activated and the desired N-deprotected labeling group-functionalized di-lysine derivative is added to the activated safety-catch resin.
  • the pendant amino groups are acylated by the carboxy-terminus of the safety-catch resin-bound peptide, which is now detached from the resin and represents an integral part of the di-lysine structure.
  • An excess of the safety-catch resin-bound peptide can be employed to insure complete reaction of the amino groups of the di-lysine construct. Optimization of the ratio of the reacting partners in this scheme optimizes the yield.
  • the protecting groups on the cMet-binding peptides are removed employing trifluoroacetic acid based cleavage protocols.
  • a cMet-binding peptide is assembled on a Rink-amide resin by automated or manual peptide coupling methods, usually employing Fmoc peptide synthesis protocols.
  • the peptide can possess a C-terminus or N-terminus functionalized with a linker or a linker-labeling group construct that may possess an additional nucleophilic group such as the ⁇ -amino group of a lysine moiety, for example.
  • Cleavage of the protecting groups is accomplished employing trifluoroacetic acid with appropriate modifiers depending on the nature of the peptide.
  • the fully deprotected peptide is then reacted with a large excess of a bifunctional electrophile such as the commercially available glutaric acid bis-N-hydroxysuccinimide ester (Tyger Scientific, Inc., Princeton, NJ).
  • a bifunctional electrophile such as the commercially available glutaric acid bis-N-hydroxysuccinimide ester (Tyger Scientific, Inc., Princeton, NJ).
  • the resulting monoamidated, mono-N-hydroxysuccinimidyl ester of glutaric acid is then treated with an additional equivalent of the same peptide, or an equivalent of a different cMet-binding peptide. Purification of the resulting material by HPLC affords the desired homo-dimeric construct bearing a suitable labeling group.
  • a modular scheme can be employed to prepare dimeric or higher multimeric constructs bearing suitable labeling groups as defined above.
  • fmoc-lysine(iV-Dde) Rink amide resin is treated with piperidine to remove the fmoc moiety.
  • a labeling function such as biotin, 5-carboxyfluorescein or N,N-dimethyl-Gly-Ser(O-t-Bu)-Cys(Acm)-Gly-OH is coupled to the nitrogen atom.
  • the resin is next treated with hydrazine to remove the iV-Dde group.
  • the resin is treated with cyanuric chloride and a hindered base such as diisopropylethylamine in a suitable solvent such as DMF, NMP or dichloromethane to provide a monofunctionalized dichlorotriazine bound to the resin.
  • a suitable solvent such as DMF, NMP or dichloromethane
  • Subsequent successive displacement of the remaining chlorine atoms by two equivalents of a cMet-binding peptide provides a resin-bound homo-dimeric labeling group-functionalized construct ( Falorni, M. et al., 1998. Tetrahedron Lett., 39:7607-7610 ; Johnson, C. et al., 1998. Tetrahedron, 54:4097-4106 ; Stankova, M. and Lebl, M., 1996.
  • the incoming peptides can be protected or unprotected as the situation warrants. Cleavage of protecting groups is accomplished employing trifluoroacetic acid-based deprotection reagents as described above, and the desired materials are purified by high performance liquid chromatography.
  • lysine derivatives can be serially employed to increase the multiplicity of the multimers.
  • the use of related, more rigid molecules bearing the requisite number of masked, or orthogonally protected nitrogen atoms to act as scaffolds to vary the distance between the cMet-binding peptides, to increase the rigidity of the construct (by constraining the motion and relative positions of the cMet-binding peptides relative to each other and the reporter) is entirely within the scope of methods A-C and all other methods described herein.
  • the cMet binding moieties of the invention also have utility in the treatment of a variety of disease states, including those associated with cellular proliferation (e.g ., hyperproliferation, e.g ., cancer).
  • the cMet binding moieties of the invention e.g., polypeptides and multimeric polypeptide constructs
  • binding polypeptides or multimeric polypeptide construct of the invention can be immobilized on a solid substrate such as a chromatographic support or other matrix material, then the immobilized binder can be loaded or contacted with the solution under conditions suitable for formation of a binding polypeptide/cMet complex.
  • the non-binding portion of the solution can be removed and the complex can be detected, for example, using an anti-HGF or anti-HGF/cMet complex antibody, or an anti-binding polypeptide antibody, or the cMet or HGF/cMet complex target can be released from the binding moiety at appropriate elution conditions.
  • Radiotherapeutic compounds of the present invention are known to those skilled in the art.
  • the compounds can be administered using many methods including, but not limited to, a single or multiple IV or IP injections, using a quantity of radioactivity that is sufficient to cause damage or ablation of the targeted cMet-expressing tissue, but not so much that substantive damage is caused to non-target (normal tissue).
  • the quantity and dose required is different for different constructs, depending on the energy and half-life of the isotope used, the degree of uptake and clearance of the agent from the body and the mass of the tumor.
  • doses can range from a single dose of about 30-50 mCi to a cumulative dose of up to about 3 Ci.
  • the radiotherapeutic compositions of the invention can include physiologically acceptable buffers, and can require radiation stabilizers to prevent radiolytic damage to the compound prior to injection.
  • Radiation stabilizers are known to those skilled in the art, and can include, for example, para-aminobenzoic acid, ascorbic acid, gentistic acid and the like.
  • a single, or multi-vial kit that contains all of the components needed to prepare the complexes of this invention, other than the radionuclide, is described.
  • a single-vial kit preferably contains a chelating ligand, a source of stannous salt, or other pharmaceutically acceptable reducing agent, and is appropriately buffered with pharmaceutically acceptable acid or base to adjust the pH to a value of about 3 to about 9.
  • the quantity and type of reducing agent used would depend on the nature of the exchange complex to be formed. The proper conditions are well known to those that are skilled in the art. It is preferred that the kit contents be in lyophilized form.
  • Such a single vial kit can optionally contain labile or exchange ligands such as glucoheptonate, gluconate, mannitol, malate, citric or tartaric acid and can also contain reaction modifiers such as diethylenetriamine-pentaacetic acid (DPTA), ethylenediamine tetraacetic acid (EDTA), or ⁇ , ⁇ , or ⁇ cyclodextrin that serve to improve the radiochemical purity and stability of the final product.
  • the kit also can contain stabilizers, bulking agents such as mannitol, that are designed to aid in the freeze-drying process, and other additives known to those skilled in the art.
  • a multi-vial kit preferably contains the same general components but employs more than one vial in reconstituting the radiopharmaceutical.
  • one vial can contain all of the ingredients that are required to form a labile Tc(V) complex on addition of pertechnetate (e.g ., the stannous source or other reducing agent).
  • pertechnetate e.g ., the stannous source or other reducing agent.
  • Pertechnetate is added to this vial, and after waiting an appropriate period of time, the contents of this vial are added to a second vial that contains the ligand, as well as buffers appropriate to adjust the pH to its optimal value. After a reaction time of about 5 to 60 minutes, the complexes of the present invention are formed. It is advantageous that the contents of both vials of this multi-vial kit be lyophilized.
  • reaction modifiers, exchange ligands, stabilizers, bulking agents, etc. can be present in either or both vials.
  • the cMet binding polypeptides and multimeric polypeptide constructs of the present invention can be used to present, treat or improve the activity of therapeutic agents such as anti-proliferative or tumoricidal agents against undesired cellular proliferation (such as occurs in neoplastic tumors, e.g ., cancer, by providing or improving their affinity for cMet and their residence time at a HGF/cMet complex on proliferating cells, such as, for example, epithelial cells) for diseases associated with cMet, including, but not limited to, diseases related to cMet activity.
  • therapeutic agents such as anti-proliferative or tumoricidal agents against undesired cellular proliferation (such as occurs in neoplastic tumors, e.g ., cancer, by providing or improving their affinity for cMet and their residence time at a HGF/cMet complex on proliferating cells, such as, for example, epithelial cells) for diseases associated with cMet, including, but not limited to, diseases related to c
  • the therapeutic agent can be a radiotherapeutic, discussed above, a drug, chemotherapeutic or tumoricidal agent, genetic material or a gene delivery vehicle, etc.
  • the cMet binding polypeptide moiety portion of the conjugate causes the therapeutic to "home" to the sites of cMet or HGF/cMet complex (i.e ., activated epithelial cells), and to improve the affinity of the conjugate for the endothelium, so that the therapeutic activity of the conjugate is more localized and concentrated at the sites of cellular proliferation.
  • these cMet binding moieties can inhibit HGF-mediated signaling events by preventing HGF from binding to cMet.
  • Such conjugates will be useful in treating hyperproliferative disorders, especially neoplastic tumor growth and metastasis, in mammals, including humans.
  • the method comprises administering to a mammal in need thereof an effective amount of a cMet binding polypeptide or multimeric polypeptide construct according to the invention conjugated with a therapeutic agent.
  • the disclosure also provides the use of such conjugates in the manufacture of a medicament for the treatment of angiogenesis associated diseases in mammals, including humans.
  • Suitable therapeutic agents for use in this aspect of the invention include, but are not limited to: antineoplastic agents, such as platinum compounds (e.g ., spiroplatin, cisplatin, and carboplatin), methotrexate, adriamycin, mitomycin, ansamitocin, bleomycin, cytosine, arabinoside, arabinosyl adenine, mercaptopolylysine, vincristine, busulfan, chlorambucil, melphalan ( e.g ., PAM, L-PAM, or phenylalanine mustard), mercaptopurine, mitotane, procarbazine hydrochloride, dactinomycin (actinomycin D), daunorubcin hydrochloride, doxorubicin hydrochloride, taxol, mitomycin, plicamycin (mithramycin), aminoglutethimide, estramustine phosphate sodium, flutamide
  • the therapeutic agent can be associated with an ultrasound contrast agent composition in which cMet binding moieties of the invention are linked to the material employed to form the vesicles as described herein.
  • the tissue can be irradiated with an energy beam (preferably ultrasonic, e.g ., with a frequency of from 0.3 to 3 MHz), to rupture or burst the microvesicles.
  • an energy beam preferably ultrasonic, e.g ., with a frequency of from 0.3 to 3 MHz
  • the therapeutic effect of the therapeutic agent can thus be enhanced by the energy released by the rupture of the microvesicles, in particular causing an effective delivery of the therapeutic agent to the targeted tissue.
  • the therapeutic agent can be associated with the targeted ultrasound contrast agent and delivered as described in US 6,258,378 .
  • the cMet binding polypeptides and multimeric polypeptide constructs of the present invention also can be used to target genetic material to cMet-expressing cells. Thus, they can be useful in gene therapy, particularly for treatment of hyperproliferative disorders.
  • genetic material or one or more delivery vehicles containing genetic material useful in treating a hyperproliferative disorder can be conjugated to one or more cMet binding moieties of the invention and administered to a patient.
  • the genetic material can include nucleic acids, such as RNA or DNA, of either natural or synthetic origin, including recombinant RNA and DNA and antisense RNA and DNA.
  • Types of genetic material that can be used include, for example, genes carried on expression vectors such as plasmids, phagemids, cosmids, yeast artificial chromosomes (YACs) and defective or "helper" viruses, antigene nucleic acids, both single and double stranded RNA and DNA and analogs thereof, such as phosphorothioate and phosphorodithioate oligodeoxynucleotides. Additionally, the genetic material can be combined, for example, with lipids, proteins or other polymers.
  • Delivery vehicles for genetic material can include, for example, a virus particle, a retroviral or other gene therapy vector, a liposome, a complex of lipids (especially cationic lipids) and genetic material, a complex of dextran derivatives and genetic material, etc.
  • the constructs of the invention can be utilized in gene therapy for treatment of hyperproliferative disorders.
  • genetic material, or one or more delivery vehicles containing genetic material, e.g ., useful in treating a hyperproliferative disorder can be conjugated to one or more cMet binding polypeptides or multimeric polypeptide constructs of the invention and administered to a patient.
  • Constructs including genetic material and the cMet-binding moieties of the invention can be used, in particular, to selectively introduce genes into proliferating cancer cells (e.g ., epithelial cells), which can be useful to treat cancer.
  • proliferating cancer cells e.g ., epithelial cells
  • Therapeutic agents and the cMet binding moieties of the invention can be linked or fused in known ways, optionally using the same type of linkers discussed elsewhere in this application.
  • Preferred linkers will be substituted or unsubstituted alkyl chains, amino acid chains, polyethylene glycol chains, and other simple polymeric linkers known in the art. More preferably, if the therapeutic agent is itself a protein, for which the encoding DNA sequence is known, the therapeutic protein and cMet binding polypeptide can be coexpressed from the same synthetic gene, created using recombinant DNA techniques, as described above.
  • the coding sequence for the cMet binding polypeptide can be fused in frame with that of the therapeutic protein, such that the peptide is expressed at the amino- or carboxy-terminus of the therapeutic protein, or at a place between the termini, if it is determined that such placement would not destroy the required biological function of either the therapeutic protein or the cMet binding polypeptide.
  • a particular advantage of this general approach is that concatamerization of multiple, tandemly arranged cMet binding polypeptides is possible, thereby increasing the number and concentration of cMet binding sites associated with each therapeutic protein. In this manner cMet binding avidity is increased, which would be expected to improve the efficacy of the recombinant therapeutic fusion protein.
  • constructs including cMet binding polypeptides of the present invention can themselves be used as therapeutics to treat a number of diseases associated with cMet activity.
  • a protein or other molecule e.g ., a growth factor, hormone etc.
  • constructs including such binding moieties could be useful as therapeutics.
  • constructs containing such binding moieties also could be useful as therapeutics.
  • constructs including cMet binding polypeptides that inhibit the binding of HGF to cMet can be used as anti-neoplastic agents.
  • constructs including cMet binding polypeptides that inhibit the binding of HGF to cMet, or otherwise inhibit activation of cMet can be used as anti-angiogenic agents.
  • Certain constructs of the invention including monomers, multimers and heteromultimers that inhibit activation of cMet are also discussed in the Examples, and include, for example, SEQ ID NO:2 ( FIG. 10 ).
  • the binding polypeptides and constructs thereof of the present invention are useful as therapeutic agents for treating conditions that involve endothelial and/or epithelial cells expressing cMet. Because an important function of endothelium is angiogenesis, or the formation of blood vessels, the polypeptides and constructs thereof are particularly useful for treating conditions that involve angiogenesis and/or hyperproliferation. Conditions that involve angiogenesis include, for example, solid tumors, tumor metastases and benign tumors.
  • Tumors caused by cMet activation or through angiogenesis are well known in the art and include, for example, breast, thyroid, glioblastoma, prostate, malignant mesothelioma, colorectal, hepatocellular, hepatobiliary, renal, osteosarcoma and cervical. Additional tumors and related disorders are listed in Table 1 of U.S. Patent No. 6,025,331, issued February 15, 2000 to Moses, et al. Benign tumors include, for example, hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas.
  • rheumatoid arthritis rheumatoid arthritis
  • psoriasis ocular diseases
  • ocular diseases such as diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rebeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma and wound granulation.
  • Other relevant diseases or conditions that involve blood vessel growth include intestinal adhesions, atherosclerosis, scleroderma, and hypertropic scars, and ulcers.
  • the binding polypeptides and constructs thereof of the present invention can be used to reduce or prevent uterine neovascularization required for embryo implantation, for example, as a birth control agent.
  • binding polypeptides, multimeric polypeptide constructs and constructs conjugates thereof can be administered to an individual over a suitable time course depending on the nature of the condition and the desired outcome. They binding polypeptides and constructs thereof can be administered prophylactically, e.g ., before the condition is diagnosed or to an individual predisposed to a condition.
  • the binding polypeptides multimeric polypeptide constructs and conjugates and constructs thereof can be administered while the individual exhibits symptoms of the condition or after the symptoms have passed or otherwise been relieved (such as after removal of a tumor).
  • they binding polypeptides and constructs thereof of the present invention can be administered a part of a maintenance regimen, for example to prevent or lessen the recurrence or the symptoms or condition.
  • the binding polypeptides multimeric polypeptide constructs and conjugates and constructs thereof of the present invention can be administered systemically or locally.
  • the quantity of material administered will depend on the seriousness of the condition. For example, for treatment of a hyperproliferative disorder, e.g ., in the case of neoplastic tumor growth, the position and size of the tumor will affect the quantity of material to be administered.
  • the precise dose to be employed and mode of administration must per force, in view of the nature of the complaint, be decided according to the circumstances by the physician supervising treatment.
  • dosages of the agent conjugate polypeptides, multimeric polypeptide constructs and conjugates of the present invention will follow the dosages that are routine for the therapeutic agent alone, although the improved affinity of a binding polypeptide or multimeric polypeptide construct of the invention for its target can allow for a decrease in the standard dosage.
  • Such conjugate pharmaceutical compositions are preferably formulated for parenteral administration, and most preferably for intravenous or intra-arterial administration.
  • pharmaceutical compositions can be given as a bolus, as two or more doses separated in time, or as a constant or non-linear flow infusion.
  • the term "therapeutic” includes at least partial alleviation of symptoms of a given condition.
  • the binding polypeptides, multimeric constructs and constructs conjugates thereof of the present invention do not have to produce a complete alleviation of symptoms to be useful.
  • treatment of an individual can result in a decrease in the size of a tumor or diseased area, or prevention of an increase in size of the tumor or diseased area. Treatment also can prevent or lessen the number or size of metastatic outgrowths of the main tumor(s).
  • Symptoms that can be alleviated include physiological characteristics such as cMet activity.
  • the binding polypeptides multimeric polypeptide constructs and conjugates and constructs thereof of the present invention can inhibit activity of cMet and its homologs by binding to cMet and inhibiting its activity or by binding to cMet and inhibiting HGF from activating this receptor. Such inhibition can be detected, for example, by measuring the phosphorylation state of the receptor in the presence of or after treatment with the binding polypeptides or constructs thereof.
  • a suitable dose of binding polypeptide, multimeric polypeptide constructs and conjugates or construct thereof as provided herein and measure the effect of treatment on the parameter of interest. For example, the size of the area of interest (e.g ., the tumor or lesion) can be measured before and after treatment.
  • Cells or cMet itself can be isolated from the sample and used in assays described herein.
  • the dosage of the polypeptides multimeric polypeptide constructs and conjugates and constructs thereof can depend on the age, sex, health, and weight of the individual, as well as the nature of the condition and overall treatment regimen.
  • the biological effects of the polypeptides multimeric polypeptide constructs and conjugates and constructs thereof are described herein. Therefore, based on the biological effects of the binding polypeptides multimeric polypeptide constructs and conjugates and constructs provided herein, and the desired outcome of treatment, the preferred dosage is determinable by one of ordinary skill in the art through routine optimization procedures.
  • the daily regimen is in the range of about 0.1 mg/kg to about 1 mg/kg.
  • binding polypeptides moieties and constructs conjugates thereof provided herein can be administered as the sole active ingredient, optionally together with a pharmaceutically acceptable excipient, or can be administered together ( e.g ., simultaneously or sequentially) with other binding polypeptides and constructs thereof, other therapeutic agents, or combination thereof.
  • the binding polypeptides moieties and conjugate constructs thereof can be conjugated to therapeutic agents, for example, to improve specificity, residence time in the body, or therapeutic effect.
  • therapeutic agents include, for example, other anti-proliferative compounds, and tumoricidal compounds.
  • the therapeutic agent also can include antibodies.
  • the binding polypeptide multimeric polypeptide constructs and constructs thereof of the present invention can be used as a cancer cell homing device.
  • binding polypeptide or constructs thereof can may be conjugated to nucleic acid encoding, for example, a therapeutic polypeptide, in order to target the nucleic acid to stromal cells.
  • nucleic acid conjugated binding polypeptide moiety or conjugate thereof Once exposed to the nucleic acid conjugated binding polypeptide moiety or conjugate thereof, the stromal cells can internalize and express the conjugated nucleic acid, thereby delivering the therapeutic peptide to the target cells.
  • the binding polypeptides, multimeric polypeptide constructs and conjugates and constructs thereof can be administered locally or systemically by any suitable route.
  • Suitable routes of administration include, but are not limited to, topical application, transdermal, parenteral, gastrointestinal, intravaginal, and transalveolar.
  • Compositions for the desired route of administration can be prepared by any of the methods well known in the pharmaceutical arts, for example, as described in Remington: The Science and Practice of Pharmacy, 20th ed., Lippincott, Williams and Wilkins, 2000 .
  • the binding polypeptides, multimeric polypeptide constructs and conjugates thereof can be suspended, for example, in a cream, gel or rinse that allows the polypeptides or constructs to penetrate the skin and enter the blood stream, for systemic delivery, or contact the area of interest, for localized delivery.
  • compositions suitable for topical application include any pharmaceutically acceptable base in which the polypeptides or constructs are at least minimally soluble.
  • the polypeptides, multimeric polypeptide constructs and conjugates thereof can be applied in pharmaceutically acceptable suspension together with a suitable transdermal device or "patch".
  • suitable transdermal devices for administration of the polypeptides or constructs of the present invention are described, for example, in U.S. Patent No. 6,165,458, issued December 26, 2000 to Foldvari et al. , and U.S. Patent No. 6,274,166B1, issued August 4, 2001 to Sintov et al.
  • compositions for intravenous administration are solutions in sterile isotonic aqueous buffer.
  • Other pharmaceutically acceptable carriers include, but are not limited to, sterile water, saline solution, and buffered saline (including buffers like phosphate or acetate), alcohol, vegetable oils, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, paraffin, etc.
  • the composition also can include a solubilizing agent and a local anaesthetic such as lidocaine to ease pain at the site of the injection, preservatives, stabilizers, wetting agents, emulsifiers, salts, lubricants, etc. as long as they do not react deleteriously with the active compounds.
  • a solubilizing agent such as lidocaine to ease pain at the site of the injection, preservatives, stabilizers, wetting agents, emulsifiers, salts, lubricants, etc. as long as they do not react deleteriously with the active compounds.
  • the composition may comprise conventional excipients, i.e . pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral, enteral or intranasal application which do not deleteriously react with the active compounds.
  • the ingredients will be supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent in activity units.
  • a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent in activity units.
  • the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade "water for injection" or saline.
  • an ampoule of sterile water for injection or saline can be provided so that the ingredients can be mixed prior to administration.
  • polypeptides, multimeric polypeptide constructs and conjugates thereof can be incorporated into pharmaceutically acceptable powders, pills or liquids, and suppositories for rectal or vaginal administration.
  • the polypeptides, multimeric polypeptide constructs and conjugates thereof can be suspended in a pharmaceutically acceptable excipient suitable for aerosolization and inhalation or as a mouthwash.
  • a pharmaceutically acceptable excipient suitable for aerosolization and inhalation or as a mouthwash such as atomizers and vaporizers also are included within the scope of the invention.
  • Suitable formulations for aerosol delivery of polypeptides, etc. using buccal or pulmonary routes can be found, for example in U.S. Patent No. 6,312,665B1, issued November 6, 2001 to Pankaj Modi .
  • polypeptides, multimeric polypeptide constructs and conjugates thereof of the present invention can be administered nasally or ocularly, where the polypeptide or construct is suspended in a liquid pharmaceutically acceptable agent suitable for drop-wise dosing.
  • polypeptides, multimeric polypeptide constructs and conjugates thereof of the present invention can be administered such that the polypeptide, etc. is released in the individual over an extended period of time (sustained or controlled release).
  • the polypeptide, multimeric polypeptide constructs and conjugates thereof can be formulated into a composition such that a single administration provides delivery of the polypeptide, etc. for at least one week, or over the period of a year or more.
  • Controlled release systems include monolithic or reservoir-type microcapsules, depot implants, osmotic pumps, vesicles, micelles, liposomes, transdermal patches and iontophoretic devices.
  • polypeptides, multimeric polypeptide constructs and conjugates thereof of the present invention are encapsulated or admixed in a slowly degrading, non-toxic polymer. Additional formulations suitable for controlled release of the polypeptides, multimeric polypeptide constructs and conjugates thereof provided herein are described in U.S. Patent No. 4,391,797, issued July 5, 1983, to Folkman et al.
  • Another suitable method for delivering the polypeptides of the present invention to an individual is via in vivo production of the polypeptide.
  • a gene encoding the polypeptide can be administered to the individual such that the encoded polypeptide is expressed.
  • the gene can be transiently expressed.
  • the gene encoding the polypeptide is transfected into cells that have been obtained from the patient, a method referred to as ex vivo gene therapy. Cells expressing the polypeptide are then returned to the patient's body.
  • Methods of ex vivo gene therapy are well known in the art and are described, for example, in U.S. Patent No. 4,391,797, issued March 21, 1998 to Anderson et al.
  • Example 1 Method for identification of cMet-binding polypeptides
  • a four-pronged selection strategy using a variety of peptide-displaying phage libraries was utilized to screen for cMet-binding polypeptides. Both the extracellular domain of the cMet receptor (expressed as an Fc-fusion protein) and the colorectal cancer cell line, DLD-1, which express high levels of cMet on their cell surface, were used as tools for the selections.
  • FIG. 9 illustrates the selection strategy that was employed. Briefly, 21 different selection campaign/elution combinations were performed with each library pool. An additional 10 selection campaigns representing rounds 3 and 4 using the soluble Met-Fc fusion protein were also performed. HGF elutions were at a concentration of 100 ng/mL.
  • Example 2 Determination of peptide-displaying phage binding to soluble cMet-Fc fusion protein "protein phage ELISAs"
  • Protein phage ELISAs using peptide-displaying phage isolates from the various selection campaigns were performed to determine specificity of the peptides for cMet versus an unrelated Fc-fusion protein (TRAIL-Fc). Briefly, 384-well plates were coated overnight at 4C with 0.5 ⁇ g/mL of cMet-Fc fusion protein or TRAIL-Fc fusion protein (background). The plates were blocked for 2 hours 37C with 3% (w/v) BSA in PBS containing 0.05% (v/v) Tween-20 (PBST). The plates were washed with PBST and 100 ⁇ L of peptide-displaying phage were added to each well. The plates were incubated for 2 hours at room temperature and washed with PBST. cMet-binding peptide-displaying phage were detected using an HRP-conjugated anti-M 13 aritibody.
  • HRP-conjugated anti-M 13 aritibody HRP-conjugated anti
  • the peptide-displaying phage that demonstrated a > 3-fold binding to cMet-Fc fusion protein versus TRAIL-Fc fusion protein are herein referred to as "positive hits".
  • the positive hits identified in the above screen were subjected to DNA sequencing. From subsequent sequence analysis, 187 unique peptide sequences were identified.
  • Example 3 Determination of cMet binding in a cellular model
  • 3T3 cells that over-express human cMet were used as a control cell line. Briefly, 96-well plates were seeded with 10 5 cells per well. The plates were centrifuged for 5 minutes at 1600 rpm to pellet the cells. The resulting cell layer was fixed with 0.1% (v/v) glutaraldehyde for 12 minutes at 37C. The cells were washed with PBS and subsequently blocked with 3% BSA in PBST for I hour at 37C. Peptide-displaying phage also were blocked in the above solution for 1 hour at 37C.
  • HGF competition protein ELISAs were performed in an attempt to determine whether any of the cMet-binding peptides compete with HGF for a similar binding site on cMet.
  • This competition ELISA identifies peptides that serve as "HGF antagonistic peptides", peptides that block HGF-mediated signaling events (e.g ., proliferation).
  • HGF antagonistic peptides peptides that block HGF-mediated signaling events (e.g ., proliferation).
  • the plates were blocked for 2 hours at 37C with 3% BSA in PBST.
  • the plates were washed with PBST, and 100 ⁇ L of HGF (either at 100 ng/mL or 500 ng/mL in PBST) was added to each well.
  • the plates were incubated for 30 minutes at room temperature after which the plates were washed with PBST and 70 ⁇ L of HGF (143 ng/mL or 714 ng/mL) or 70 ⁇ L of PBST was added to the respective wells. This was followed by an addition of 30 ⁇ L of peptide-displaying phage overnight culture to each well.
  • the plates were incubated for 2 hours at room temperature, washed with PBST and cMet-binding peptide-displaying phage was detected using an HRP-conjugated anti-M13 antibody.
  • cMet-binding peptides corresponding to positive phage isolates were synthesized on a solid phase matrix using 9-fluorenylmethoxycarbonyl protocols. These peptides were purified with reverse phase chromatography. Peptide masses were confirmed by electrospray mass spectrometry, and peptides were quantified by measuring absorbance at 280 nm. For synthesis, two N-terminal and two C-terminal amino acids from the phage vector sequence from which the peptide was excised were retained, and a linker, e.g ., -Gly-Gly-Gly-Lys-NH 2 was added to the C-terminus of each peptide.
  • a linker e.g ., -Gly-Gly-Gly-Lys-NH 2 was added to the C-terminus of each peptide.
  • Each peptide was N-terminally acetylated. Selected lysine residues were protected with 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl (ivDde) where appropriate.
  • the protecting group allows for selective coupling to the C-terminal lysine, is not removed during peptide cleavage, but can be removed after coupling with 2% hydrazine in DMF or 0.5 M hydroxylamine, pH 8, in water.
  • Each peptide was labeled with fluorescein on the C-terminal lysine using fluorescein (N-hydroxysuccinimide ester derivative) or fluorescein isothiocyanate (FITC) in DMF with 2% diisopropylethylamine (DIPEA).
  • fluorescein N-hydroxysuccinimide ester derivative
  • FITC fluorescein isothiocyanate
  • DIPEA diisopropylethylamine
  • the reaction was quenched by the addition of 2% hydrazine, which reacts with all free NHS-fluorescein and removes the internal protecting group.
  • the reaction was quenched by the addition of an equal volume of 0.5M hydroxylamine, pH 8.
  • the quenched reactions were then diluted with water to less than 10% DMF and then purified using C18 reverse phase chromatography.
  • the peptides were verified by analyzing them for expected mass using an LC-MS system (HP1100 HPLC with in-line SCIEX AP150 single quadrapole mass spectrometer), and the purity of the peptides was determined.
  • Fluorescence anisotropy measurements were performed in 384-well microplates in a volume of 10 ⁇ L in binding buffer (PBS, 0.01% Tween-20, pH 7.5) using a Tecan Polarion fluorescence polarization plate reader (Caracas, Venezuela). The concentration of fluorescein-labeled peptide was held constant (20 nM) and the concentration of cMet-Fc fusion protein (or similar target) was varied. Binding mixtures were equilibrated for 10 minutes in the microplate at 30C before measurement. The observed change in anisotropy was fit to the equation below via nonlinear regression to obtain the apparent K D .
  • Peptide competition fluorescence polarization assays were performed to determine which peptides compete with each other for binding to cMet. This would identify potential heteromeric peptide complexes that exhibit higher affinity for the cMet receptor than an individual peptide alone.
  • Compound B was treated with a 10-fold excess of glutaric acid bis NHS ester (Tyger Scientific, Princeton, NJ) and ⁇ 20-fold excess of diisopropylethylamine at ambient temperature in DMF for 30 minutes. The reaction mixture was diluted with ether (15-fold by volume) which led to the precipitation of the mono-NHS ester of the glutarylated peptide.
  • the ether was decanted and the solid washed thrice more with ether, which removed any traces of unreacted glutaric acid bis NHS ester.
  • the resulting solid was resuspended in dry DMF and the compound A (1 equiv) was added followed by diisopropylethylamine (20 equiv) and the mixture was stirred for 24 hours at ambient temperature.
  • the mixture was diluted with water (50-fold) and the mixture was directly loaded onto a reverse-phase HPLC column, which was eluted with a gradient of acetonitrile (0.1% TFA) into water (0.1% TFA). Fractions containing the desired product were combined and lyophilized to provide the desired materials.
  • the semi-solid thus obtained was dissolved in dry DMF (0.2 mL) and the peptide SEQ ID NO:16-(6-PnAO-Glut)) (10 mg, 0.0032 mmol) and diisopropylethylamine (10 mg, 0.08 mmol) were added and stirred the reaction mixture for 24 h at room temperature.
  • the reaction mixture was diluted with water (10 mL), loaded onto a reversed-phase (C18) HPLC column, and eluted with water (0.1% TFA)-acetonitrile (0.1% TFA) system.
  • SK-LMS-1 leomyosarcoma cell line
  • SK-LMS-1 cells were seeded on 96-well plates at a density of 2000 cells/well. After a 24 hour incubation at 37°C, the cells were starved in culture media containing 0.1%BSA instead of 10% fetal bovine serum for 36 hours at 37C. Fresh starvation media with or without a cMet-binding peptide (10 ⁇ M) was added to the respective wells and the cells were incubated for 2 hours at 37°C.
  • DMF was used as the control vehicle and did not receive a cMet-binding peptide.
  • HGF was then added at a concentration of either 50 ng/mL or 100 ng/mL and the cells were incubated for an additional 12 hours at 37C. Proliferation was assessed by measuring the incorporation of BrdU (Calbiochem, San Diego, CA) as described by the manufacturer. Results are shown for SEQ ID NO:2 ( FIG. 10 ).
  • the binding constants were determined for the peptide dimers (shown in FIGS. 13A-13C ) binding to immobilized cMet-Fc.
  • cMet-Fc Three densities of cMet-Fc (R&D Systems) were cross- linked to the dextran surface of a CM5 sensor chip by the standard amine coupling procedure (3 :M solution diluted 1:100, 1:50, or 1:20 with 50 mM acetate, pH 5.5). Flow cell I was activated and then blocked to serve as a reference subtraction. Final immobilization levels achieved:
  • Example 11 Enhancing the serum residence of cMet-binding peptides: Conjugation to maleimide
  • Peptides that include disulfides can be derivatized with maleimide in one of several ways.
  • a third cysteine can be added at the carboxy terminus.
  • the added cysteine is protectted with protecting group that is orthogonal to the type of groups used for the cysteines that are to form the disulfide.
  • the disulfide is formed by selectively deprotecting the intended cysteines and oxidizing the peptide.
  • the final cysteine is then deprotected and the peptide reacted with a large molar excess of a bismaleimide.
  • the resulting compound has one of the maleimides free to react with serum albumin or other thiol-containing serum proteins.
  • a cyclic peptide of the present invention is synthesized with a lysine-containing C-terminal extention, such as -GGGK (SEQ ID NO:15). Lysines of the cMet-binding motif are protected with ivDde and the C-terminal lysine is deprotected. This lysine is reacted with a maleimide-containing compound, such as N-[e-maleimidocaproyloxy]succinimide ester (Pierce Biotechnology, Rockford, IL) or N-[a-Maleimidoacetoxy]succinimide ester (Pierce Biotechnology).
  • a maleimide-containing compound such as N-[e-maleimidocaproyloxy]succinimide ester (Pierce Biotechnology, Rockford, IL) or N-[a-Maleimidoacetoxy]succinimide ester (Pierce Biotechnology).
  • Example 12 Enhancing the serum residence of cMet-binding peptides: Conjugation to a moiety, that binds serum albumin non-covalently
  • Polypeptides having a molecular weight less than 50-60 kDa are rapidly excreted. Many small molecules, such as fatty acids, bind to serum albumin. Attaching a fatty acid or other serum albumin binding moiety to a peptide causes it to bind non-covalently to serum albumin and can greatly prolong serum residence.
  • Fatty acids attached to peptides of the present invention should contain at least 12 carbons, preferably at least 14 carbons and, more preferably at least 16 carbons.
  • the fatty acid could be straight-chain or branched.
  • the fatty acid could be saturated or unsaturated. Palmate (CH 3 -(CH 2 ) 14 -CO- is a preferred fatty acid.
  • serum-albumin-binding moieties can be conjugated to any one of the peptides or multimeric polypeptide binding constructs herein disclosed.
  • the serum-albumin-binding moiety can be joined to the cMet-binding peptide through a linker.
  • the linker can be peptidic or otherwise, such as PEG. Linkers of zero to about thirty atoms are preferred. It is preferred that the linker be hydrophilic.
  • the serum-albumin-binding moiety can be conjugated to the cMet-binding peptide or construct at either end or though a side group of an appended amino acid. Suitable side groups include lysine and cysteine. Such compounds also can comprise, for example, chelators for radionuclides, or other detectable labels or therapeutic constructs, as discussed herein. A cMet peptide or construct joined to a serum-albumin-binding moiety will bind cMet.
  • Example 13 Enhancing the serum residence of cMet-binding peptides: Conjugation to PEG
  • Attachment of PEG to proteins and peptides enhances the serum residence of these molecules. Attachment of PEG (linear or branched) to a cMet-binding peptide or multimeric polypeptide construct is expected give substantial enhancement of serum residence time.
  • the molecular weight of the PEG be at least 10 kDa, more preferably at least 20 kDa, and most preferably 30 kDa or more.
  • the PEG can be attached at the N- or C-terminus. Methods of attaching PEG to peptides are well known in the art. PEG can be attached to reactive side groups such as lysine or cysteine.
  • Example 14 Enhancing the serum residence of cMet-binding peptides: fusion to serum protein
  • Proteins comprising serum albumin (SA) and other proteins have enhanced serum residence times.
  • the amino-acid sequence of human SA (hSA) is shown in Table 10.
  • Table 11 1 shows a fusion protein comprising of (SEQ ID NO:21), mature hSA, and SEQ ID NO:22.
  • the cMet-binding peptides are separated from mature hSA by linkers that are rich in glycine to allow flexible spacing.
  • linkers that are rich in glycine to allow flexible spacing.
  • Chemical groups, such as maleimide and alpha bromo carboxylates react with the unpaired cysteine (residue 34) to form stable adducts.
  • hSA fusion proteins so that the adduct will bind a radionuclide.
  • hSA or an hSA derivative can be reacted with a bismaleimide and a chelator carrying a reactive thiol could be reacted with the bismaleimide-derivatized hSA.
  • Example 15 Pretargeting radioactivity or toxins to cMet expressing tumors
  • the present invention provides methods of increasing active agent localization at a target cell site of a mammalian recipient.
  • the methods include, for example, a) administering to a recipient a fusion protein comprising a targeting moiety and a member of a ligand-anti-ligand binding pair; b) thereafter administering to the recipient a clearing agent capable of directing the clearance of circulating fusion protein via hepatocyte receptors of the recipient, wherein the clearing agent incorporates a member of the ligand-anti-ligand binding pair; and c) subsequently administering to the recipient an active agent comprising a ligand/anti-ligand binding pair member.
  • hexoses particularly the hexoses galactose, glucose, mannose, mannose-6-phosphate, N-acetylglucosamine, pentamannosyl phosphate, N-acetylgalactosamine, thioglycosides of galactose, and mixtures thereof are effective in causing hepatic clearance. Binding of sugars to hepatic receptors is not, however, the only means of directing a molecule to the liver.
  • CEA carcinoembryonic antigen
  • YPELPK As a clearance agent, one fuses this sequence via a linker to a moiety that binds the fusion protein (Ab). For example, if the Ab has affinity for DOTA/Re, one would make a derivative having YPELPK attached to DOTA/Re; for example, rvYPELPKpsGGG-DOTA. 'rvYPELPKps' is a fragment of CEA which includes the YPELPK sequence identified by Thomas el al. (supra). Any convenient point on DOTA can be use for attachment. RVYPELPKPSGGG-DOTA/cold Re would then be used as a clearing agent. The Fab corresponding to the fusion Ab would have affinity for the clearing agent of Kd ⁇ 100 nM, preferably Kd ⁇ 10 nM, and most preferably Kd ⁇ 1 nM.
  • the therapeutic agent would contain DOTA/ 185 Re.
  • the therapeutic agent would contain two or more DOTA moieties so that the Ab immobilized on the tumor would bind the bis-DOTA compound with high avidity.
  • the two DOTA moieties would preferably be connected with a hydrophilic linker of ten to thirty units of PEG.
  • PEG is a preferred linker because it is not degraded, promotes solubility.
  • Ten to thirty units of PEG is not sufficient to give the bis DOTA compound a very long serum residence time. A half life of 30 minutes to 10 hours is acceptable. The serum half life should be longer than the radioactive half life of the radionuclide used so that most of the radiation is delivered to the tumor or to the external environment.
  • a "fusion protein" of the present invention comprises at least one cMet-binding peptide fused to the amino terminus or the carboxy terminus of either the light chain (LC) or the heavy chain (HC) of a human antibody.
  • two or more cMet-binding peptides are fused to the antibody.
  • the antibody is picked to have high affinity for a small molecule that can be made radioactive or have a toxin attached.
  • the affinity of the Fab corresponding to the Ab has affinity for the small molecule with K d less than 100 nM, more preferably less than 10 nM, and most preferably less than 1 nM.
  • the small molecule could be a chelator capable of binding a useful radioactive atom, many of which are listed herein.
  • the small molecule could be a peptide having one or more tyrosines to which radioactive iodine can be attached without greatly affecting the binding property of the peptide.
  • CMBP cMet-binding peptide
  • each fusion protein will present two copies of each of the fused peptides.
  • the fusion protein is produced in eukaryotic cells so that the constant parts of the HC will be glycosylated.
  • the cells are mammalian cells, such as CHO cells.
  • the fusion proteins are injected into a patient and time is allowed for the fusion protein to accumulate at the tumor.
  • a clearing agent is injected so that fusion protein that has not become immobilized at the tumor will be cleared.
  • the antibody combining site has been used to target to the tumor and biotin/avidin or biotin/streptavidin has been used to attach the radioactive or toxic agent to the immobilized antibody.
  • the biotin/avidin or streptavidin binding is essentially irreversible.
  • a clearing agent that will cause fusion protein not immobilized at the tumor to clear can be administered between 2 and 48 hours of the injection of the fusion protein. Because the clearance agent is monomeric in the moiety that binds the antibody, complexes of clearance agent and immobilized fusion protein will not have very long life times. Within 4 to 48 hours of injecting clearance agent, the immobilized antibody will have lost any clearance agent that binds there.
  • the active agent is, preferably, dimeric in the moiety that binds the fusion protein. The active agent is injected between 2 and - 48 hours of injection of clearance agent.
  • Example 16 Binding of cMet binding peptides / avidin HRP complex to MDA-MB-231 cells
  • MDA-MB231 cells were obtained from ATCC and grown as monolayer culture in their recommended media plus 1 mL/L pen/strep (InVitrogen, Carlsbad, CA). Cells were split the day before the assay, 35000 cells were added to each well of a 96-well plate.
  • the experiment was performed at several different concentrations of peptide/neutravidin-HRP, from 0.28 nM to 33.33 nM, to generate saturation binding curves for derivatives without a J spacer and with a single J spacer ( FIG. 14 ), and 0.28 nM to 16.65 nM to generate a saturation binding curve for the derivative with the JJ spacer ( FIG. 14 ).
  • the background binding of the control peptide/neutravidin HRP complex was subtracted from the binding of the SEQ ID NO:16 derivatives in complex with neutravidin-HRP for each concentration tested. Therefore, absorbance on the Y-axis of FIG.
  • the neutravidin-HRP assay with biotinylated peptides identified with phage display was useful for identifying peptides capable of binding to an immobilized target even when the affinity of the monomeric binding sequence is too low for an ELISA-type assay (with washing steps after binding) to work well. Table 6.
  • cMet-binding peptide sequences CLASS IX TN9 #3 SEQ ID NO: Isolate Sequence SEQ ID NO:6 602-G12, SETRPTEAGSCHCSGPPTFECWCYGTEPTE SEQ ID NO:7 604-G01, SETRPTEAGSCYCSGPPRFECWCYETEPTE SEQ ID NO:8 610-G02, SETRPTEAGSCYCGGPPSFECWCYGTEPTE SEQ ID NO:9 627-G06, SETRPTESGSCHCSGPPTFECWCYGTEPTE SEQ ID NO:10 630-C03, SETRPTEGGSCYCGGPPTFECWCYGTEPTE SEQ ID NO:11 633-G08, SETRPTEEGSCHCSGPPAFECWCYGTEPTE SEQ ID NO:12 631-D03, SETRPTEDGSCHCSGPPRFECWCYGTEPTE SEQ ID NO:13 633-G12, SETRPTEAGSCHCSGPPTFECWCYSTEPTE
  • X1 is any amino acid other than C, preferably S
  • X2 is any amino acid other than C, preferably H, Y, or N
  • X3 is any amino acid other than C, preferably S or G
  • X4 is any amino acid other than C, preferably T
  • X5 is any amino acid other than C, preferably E
  • X6 is any amino acid other than C, preferably W
  • X7 is any amino acid other than C, preferably Y
  • X8 is any amino acid other than C, preferably G, D, A, E, or S
  • X9 is any amino acid other than C, preferably T or S
  • X10 is any amino acid other than C, preferably E or D.
  • Table 9 cMet-binding heteromeric peptide complexes PAIR I SEQ ID NO: Isolate CLASS SEQ ID NO:14 130-E10 XI SEQ ID NO:4 551-H10 V PAIR II SEQ ID NO: Isolate CLASS SEQ ID NO:3 548-F07 V SEQ ID NO:4 551-H10 V PAIR III SEQ ID NO: Isolate CLASS SEQ ID NO:4 551-H10 V SEQ ID NO:5 545-H12 VIII
  • Table 11 Amino-acid Sequence of SEQ ID NO:21::HSA::SEQ IDNO:22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Claims (8)

  1. Polypeptide ou polypeptide multimètre comprenant une séquence d'acides aminés : Gly-X1-Cys-X2-Cys-X3-Gly-Pro-Pro-X4-Phe-X5-Cys-X6-Cys-X7-X8-X9-X10-Pro (séquence SEQ ID n° 1), dans laquelle
    X est Ser ;
    X2 est His, Tyr ou Asn ;
    X3 est Ser ou Gly ;
    X4 est un acide aminé autre que Cys ;
    X5 est Glu ;
    X6 est Trp ;
    X7 est Tyr ;
    X8 est Gly, Asp, Ala, Glu ou Ser ;
    X9 est Thr ou Ser ; et
    X10 est Glu ou Asp.
  2. Polypeptide ou polypeptide multimère conforme à la revendication 1, comprenant la séquence d'acides aminés de la séquence SEQ ID n° 6,7, 8, 9, 10, 11, 12 ou 13.
  3. Polypeptide ou polypeptide multimère conforme à la revendication 1, comprenant la séquence d'acides aminés de la séquence SEQ ID n° 7.
  4. Polypeptide ou polypeptide multimère conforme à la revendication 1, consistant en la séquence d'acides aminés de la séquence SEQ ID n° 7.
  5. Composition pharmaceutique devant être utilisée pour traiter une pathologie impliquant l'activation de c-Met, comprenant un polypeptide ou un polypeptide multimère conforme à la revendication 1.
  6. Composition devant être utilisée conformément à la revendication 5, dans laquelle la pathologie est une tumeur solide.
  7. Composition devant être utilisée conformément à la revendication 6, dans laquelle la tumeur est sélectionnée à partir du groupe constitué des tumeurs suivantes : tumeur du sein, de la thyroïde, glioblastome, tumeur de la prostate, mésothéliome malin, tumeur colorectale, hépatocellulaire, hépatobiliaire, rénale, ostéosarcome et tumeur cervicale.
  8. Procédé de purification de c-Met ou d'un complexe comprenant c-Met et HGF à partir d'une solution le contenant, impliquant :
    la mise en contact de la solution avec au moins un polypeptide ou un polypeptide multimère conforme à la revendication 1 ; et
    la séparation du polypeptide ou du polypeptide multimère de la solution.
EP08008144A 2003-03-03 2004-03-03 Peptides qui lient spécifiquement le récepteur HGF (CMET) et utilisations associées Expired - Lifetime EP1944312B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DK10185426.3T DK2284180T3 (en) 2003-03-03 2004-03-03 Uses of peptides that specifically bind to the HGF receptor (cMET)
EP10185426.3A EP2284180B1 (fr) 2003-03-03 2004-03-03 Utilisations de peptides qui lient spécifiquement le récepteur HGF (cMET)
PL15157779T PL2949658T3 (pl) 2003-03-03 2004-03-03 PEPTYDY SPECYFICZNIE WIĄŻĄCE SIĘ Z RECEPTOREM HGF (cMET) I ICH ZASTOSOWANIA
PL08008144T PL1944312T3 (pl) 2003-03-03 2004-03-03 Peptydy, które specyficznie wiążą receptor HGF (CMET) i ich zastosowanie
EP15157779.8A EP2949658B1 (fr) 2003-03-03 2004-03-03 Peptides qui lient spécifiquement le récepteur HGF (CMET) et utilisations associées
CY181100929T CY1120683T1 (el) 2003-03-03 2018-09-06 ΠΕΠΤΙΔΙΑ ΕΙΔΙΚΑ ΔΕΣΜΕΥΟΜΕΝΑ ΜΕ ΥΠΟΔΟΧΕΑ HGF (cMet) ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45158803P 2003-03-03 2003-03-03
EP04716901A EP1603935A4 (fr) 2003-03-03 2004-03-03 PEPTIDES PRESENTANT UNE FIXATION SPECIFIQUE AVEC LE RECEPTEUR DE HGF (cMET) ET SES UTILISATIONS

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP04716901A Division EP1603935A4 (fr) 2003-03-03 2004-03-03 PEPTIDES PRESENTANT UNE FIXATION SPECIFIQUE AVEC LE RECEPTEUR DE HGF (cMET) ET SES UTILISATIONS
EP04716901.6 Division 2004-03-03

Related Child Applications (5)

Application Number Title Priority Date Filing Date
EP15157779.8A Division EP2949658B1 (fr) 2003-03-03 2004-03-03 Peptides qui lient spécifiquement le récepteur HGF (CMET) et utilisations associées
EP10185426.3A Division EP2284180B1 (fr) 2003-03-03 2004-03-03 Utilisations de peptides qui lient spécifiquement le récepteur HGF (cMET)
EP10185426.3A Previously-Filed-Application EP2284180B1 (fr) 2003-03-03 2004-03-03 Utilisations de peptides qui lient spécifiquement le récepteur HGF (cMET)
EP10185256.4 Division-Into 2010-10-01
EP10185426.3 Division-Into 2010-10-01

Publications (2)

Publication Number Publication Date
EP1944312A1 EP1944312A1 (fr) 2008-07-16
EP1944312B1 true EP1944312B1 (fr) 2012-06-27

Family

ID=32962606

Family Applications (4)

Application Number Title Priority Date Filing Date
EP10185426.3A Expired - Lifetime EP2284180B1 (fr) 2003-03-03 2004-03-03 Utilisations de peptides qui lient spécifiquement le récepteur HGF (cMET)
EP08008144A Expired - Lifetime EP1944312B1 (fr) 2003-03-03 2004-03-03 Peptides qui lient spécifiquement le récepteur HGF (CMET) et utilisations associées
EP04716901A Withdrawn EP1603935A4 (fr) 2003-03-03 2004-03-03 PEPTIDES PRESENTANT UNE FIXATION SPECIFIQUE AVEC LE RECEPTEUR DE HGF (cMET) ET SES UTILISATIONS
EP15157779.8A Expired - Lifetime EP2949658B1 (fr) 2003-03-03 2004-03-03 Peptides qui lient spécifiquement le récepteur HGF (CMET) et utilisations associées

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP10185426.3A Expired - Lifetime EP2284180B1 (fr) 2003-03-03 2004-03-03 Utilisations de peptides qui lient spécifiquement le récepteur HGF (cMET)

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP04716901A Withdrawn EP1603935A4 (fr) 2003-03-03 2004-03-03 PEPTIDES PRESENTANT UNE FIXATION SPECIFIQUE AVEC LE RECEPTEUR DE HGF (cMET) ET SES UTILISATIONS
EP15157779.8A Expired - Lifetime EP2949658B1 (fr) 2003-03-03 2004-03-03 Peptides qui lient spécifiquement le récepteur HGF (CMET) et utilisations associées

Country Status (13)

Country Link
US (6) US20050214859A1 (fr)
EP (4) EP2284180B1 (fr)
JP (4) JP5466350B2 (fr)
AU (2) AU2004217894B2 (fr)
CA (1) CA2517939C (fr)
CY (1) CY1120683T1 (fr)
DK (2) DK2949658T3 (fr)
ES (3) ES2692166T3 (fr)
HU (1) HUE039154T2 (fr)
PL (2) PL1944312T3 (fr)
PT (1) PT2949658T (fr)
SI (1) SI2949658T1 (fr)
WO (1) WO2004078778A2 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
EP1587944A4 (fr) 2002-03-01 2007-03-21 Dyax Corp Peptides de liaison kdr et vegf/kdr et leur utilisation a des fins diagnostiques et therapeutiques
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
DK2949658T3 (en) * 2003-03-03 2018-10-01 Dyax Corp Peptides that specifically bind HGF receptor (cMet) and uses thereof
NO20034350D0 (no) * 2003-09-29 2003-09-29 Amersham Health As Optisk avbilding av kolorektal kreft
US20060008844A1 (en) * 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
EP1810037B1 (fr) 2004-10-20 2010-07-21 PEAS Institut AB Evaluation de l'activite biologique du facteur de croissance des hepatocytes (hgf)
WO2008005531A2 (fr) * 2006-07-07 2008-01-10 Washington State University Research Foundation Régulation du récepteur c-met par des ligands du récepteur de l'angiotensine iv (at4)
US8236761B2 (en) 2006-07-07 2012-08-07 Washington State University Research Foundation C-Met receptor regulation by angiotensin IV (AT4) receptor ligands
EP2114427B1 (fr) 2007-01-30 2014-06-25 New York University Peptides destinés à être utilisés dans un traitement d'états associés à de l'oxyde nitrique
KR20150017387A (ko) * 2007-05-16 2015-02-16 지이 헬스케어 에이에스 영상화를 위한 표지된 ｈｇｆ 결합성 펩티드
GB0718957D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Optical imaging agents
GB0718967D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Peptide imaging agents
US20100196272A1 (en) 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
GB0918321D0 (en) 2009-10-20 2009-12-02 Ge Healthcare As Cyclic peptide synthesis
CN102762984A (zh) 2009-11-05 2012-10-31 弗吉尼亚大学专利基金会 用于检测作为癌症生物标志的网蛋白-1的组合物和方法
GB201013808D0 (en) 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
GB201103696D0 (en) * 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201116733D0 (en) 2011-09-28 2011-11-09 Ge Healthcare As Peptide margin imaging agents
GB201116862D0 (en) 2011-09-30 2011-11-09 Ge Healthcare As Infusion imaging method
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
WO2014074907A1 (fr) * 2012-11-09 2014-05-15 Indi Molecular, Inc. Agents de capture spécifiques de c-met, compositions et procédés d'utilisation et de fabrication
CN106913865A (zh) 2013-04-18 2017-07-04 阿尔莫生物科技股份有限公司 使用白细胞介素‑10治疗疾病和病症的方法
EP3010527B1 (fr) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Méthode d'évaluation de l'identité et de la stabilité d'une protéine
US9387151B2 (en) 2013-08-20 2016-07-12 Anutra Medical, Inc. Syringe fill system and method
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
MX2016004822A (es) 2013-10-28 2016-08-17 Ngm Biopharmaceuticals Inc Modelos de cancer y metodos asociados.
RU2016122957A (ru) 2013-11-11 2017-12-19 Армо Байосайенсиз, Инк. Способы применения интерлейкина-10 для лечения заболеваний и расстройств
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
WO2015187295A2 (fr) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Méthodes permettant de faire baisser le cholestérol sérique
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
US10806803B2 (en) 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
EP3180431A1 (fr) * 2014-08-11 2017-06-21 Miti Biosystems GmbH Peptides cycliques exprimés par un matériel génétique
EP3197346B1 (fr) * 2014-09-22 2020-02-26 National Health Research Institutes Utilisation de 5-méthoxytryptophane comme agent de diagnostic de maladies inflammatoires
AU2015333827A1 (en) 2014-10-14 2017-04-20 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
KR20170084033A (ko) 2014-10-22 2017-07-19 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위해 인터루킨-10을 사용하는 방법
WO2016126615A1 (fr) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
WO2016191587A1 (fr) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Interleukine 10 pégylée utilisée pour le traitement du cancer
EP3302528A1 (fr) 2015-05-29 2018-04-11 Armo Biosciences, Inc. Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
NZ738675A (en) 2015-06-15 2019-10-25 Univ Leland Stanford Junior Methods and compositions for treating aging-associated conditions
WO2017035232A1 (fr) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
CA3026074A1 (fr) * 2016-06-01 2017-12-07 M3 Biotechnology, Inc. Composes de l'amide n-hexanoique-l-tyrosine-l-isoleucine-(6)-aminohexanoique et leur utilisation pour traiter les maladies neurodegeneratives
WO2018022603A1 (fr) 2016-07-25 2018-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Procédés de production de précurseurs et de peptides marqués au 18f, peptides marqués de liaison à c-met et procédés pour leur utilisation
WO2018052002A1 (fr) * 2016-09-13 2018-03-22 第一三共株式会社 PEPTIDE DE LIAISON À LA Thrombospondine 1
US11739163B2 (en) 2016-09-29 2023-08-29 Aebi Ltd. Therapeutic multi-targeting constructs and uses thereof
US11007272B1 (en) 2016-10-07 2021-05-18 Navidea Biopharmaceuticals, Inc. Compounds and methods for diagnosis and treatment of viral infections
GB201804835D0 (en) * 2018-03-26 2018-05-09 Ge Healthcare As Formulation and method of preparation
GB2598676A (en) 2019-06-14 2022-03-09 Edinburgh Molecular Imaging Ltd Compounds and methods of use
EP4058466A1 (fr) 2019-11-13 2022-09-21 Amunix Pharmaceuticals, Inc. Polypeptides xten à code à barres, compositions associées et leurs procédés de production et d'utilisation
JP7162853B1 (ja) 2021-07-02 2022-10-31 ペプチスター株式会社 液相ペプチド合成用担体結合ペプチドの分析方法
WO2023133595A2 (fr) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Méthodes de dosage et d'administration ex vivo de particules lipidiques ou de vecteurs viraux ainsi que systèmes et utilisations associés
WO2023193015A1 (fr) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Polythérapies d'agoniste de récepteur de cytokine et de vecteur viral
WO2023225273A1 (fr) 2022-05-20 2023-11-23 Navidea Biopharmaceuticals, Inc. Véhicules d'administration de médicament ciblant cd206 portant de nouvelles charges utiles de médicament bisphosphonate par l'intermédiaire d'un lieur dégradable

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4131648A (en) 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4180646A (en) 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4391797A (en) 1977-01-05 1983-07-05 The Children's Hospital Medical Center Systems for the controlled release of macromolecules
US4718433A (en) 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
DE3313946A1 (de) 1983-04-15 1984-10-18 Schering AG, 1000 Berlin und 4709 Bergkamen Mikropartikel und gasblaeschen enthaltende ultraschall-kontrastmittel
DE3834705A1 (de) 1988-10-07 1990-04-12 Schering Ag Ultraschallkontrastmittel aus gasblaeschen und fettsaeure enthaltenden mikropartikeln
DE3313947A1 (de) 1983-04-15 1984-10-18 Schering AG, 1000 Berlin und 4709 Bergkamen Mikropartikel und gasblaeschen enthaltende ultraschall-kontrastmittel
US4900540A (en) 1983-06-20 1990-02-13 Trustees Of The University Of Massachusetts Lipisomes containing gas for ultrasound detection
US4899755A (en) 1985-05-08 1990-02-13 The General Hospital Corporation Hepatobiliary NMR contrast agents
MX174467B (es) 1986-01-23 1994-05-17 Squibb & Sons Inc 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US4844882A (en) 1987-12-29 1989-07-04 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent
IE61591B1 (en) 1987-12-29 1994-11-16 Molecular Biosystems Inc Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
ATE173336T1 (de) 1989-08-28 1998-11-15 Gen Hospital Corp Hydroxy-aryl metallchelate für bildformung zur nmr diagnose
US5118797A (en) 1989-08-28 1992-06-02 E. R. Squibb & Sons, Inc. Rhenium tris dioxime complexes
US5123414A (en) 1989-12-22 1992-06-23 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5773024A (en) 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5305757A (en) 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5230882A (en) 1989-12-22 1993-07-27 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5871959A (en) * 1989-12-27 1999-02-16 The United States Of America As Represented By The Department Of Health And Human Services Method of producing hepatocycte growth factor/scatter factor and related cell lines
CA2034042C (fr) 1990-01-18 1999-08-17 Adrian D. Nunn Produits d'addition de l'acide boronique et de complexes rhenium-dioxime et technetium-99m-dioxime, contenant un groupe a activite biochimique
IN172208B (fr) 1990-04-02 1993-05-01 Sint Sa
US5578292A (en) 1991-11-20 1996-11-26 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
US5445813A (en) 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
US5556610A (en) 1992-01-24 1996-09-17 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method
US5183653A (en) 1990-04-13 1993-02-02 E. R. Squibb & Sons, Inc. Boronic acid adducts of metal dioxime complexes useful in labelling proteins and other amine-containing compounds
US5137928A (en) 1990-04-26 1992-08-11 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
AU636481B2 (en) 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
US5173298A (en) 1990-09-27 1992-12-22 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
CA2101942C (fr) 1991-02-08 2001-01-30 Richard T. Dean Polypeptides marques au technetium-99m pour l'imagerie
US5849261A (en) 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
ATE221915T1 (de) 1991-02-22 2002-08-15 American Cyanamid Co Identifizierung eines menschlichen rezeptor- tyrosinkinasegens
GB9106686D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
GB9106673D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
EP0586524B2 (fr) 1991-06-03 2000-11-02 Nycomed Imaging As Ameliorations apportees a ou concernant des agents contrastants
US5607661A (en) 1991-07-05 1997-03-04 Nycomed Imaging As Aggregates of x-ray microparticles for ultrasound imaging
US5808091A (en) 1991-10-29 1998-09-15 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia localizing moiety
GB9200388D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
GB9200391D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
GB9200387D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
IL104084A (en) 1992-01-24 1996-09-12 Bracco Int Bv Sustainable aqueous suspensions of pressure-resistant and gas-filled blisters, their preparation, and contrast agents containing them
US5861301A (en) 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5316921A (en) * 1992-05-18 1994-05-31 Genentech, Inc. Single-chain hepatocyte growth factor variants
ES2181689T3 (es) * 1992-05-18 2003-03-01 Genentech Inc Variantes del factor de crecimiento de hepatocitos.
WO1994003644A1 (fr) * 1992-08-10 1994-02-17 Cambridge Neuroscience, Inc. Inhibiteurs de la proliferation cellulaire, preparation et utilisation
DK0666868T4 (da) 1992-10-28 2006-09-18 Genentech Inc Anvendelse af anti-VEGF-antistoffer til behandling af cancer
US5608110A (en) 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
IL110185A (en) 1993-07-02 1999-05-09 Molecular Biosystems Inc Method for making encapsulated gas microspheres from heat denatured protein in the absence of oxygen gas
JPH09500140A (ja) 1993-07-19 1997-01-07 レゾリューション・ファーマスーティカルズ・インコーポレーテッド Ｎ▲下３▼ｓ立体配置を有するヒドラジノ型放射性核種キレート形成剤
US5798091A (en) 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
US5574140A (en) 1993-09-03 1996-11-12 Resolution Pharmaceutical Inc. Hydrazino-type N2 S2 chelators
HU225495B1 (en) 1993-12-15 2007-01-29 Bracco Research Sa Gas mixtures useful as ultrasound contrast media
GB9402867D0 (en) 1994-02-15 1994-04-06 Nycomed Imaging As Improvements in or relating to contrast agents
JPH09510093A (ja) 1994-03-08 1997-10-14 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 血管内皮細胞増殖因子２
JP2891647B2 (ja) 1994-03-11 1999-05-17 株式会社日本触媒 有機スルフィド化合物及びその製造方法
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US5582814A (en) 1994-04-15 1996-12-10 Metasyn, Inc. 1-(p-n-butylbenzyl) DTPA for magnetic resonance imaging
DE69534990T2 (de) 1994-04-20 2006-10-05 Amersham Health Salutar Inc. Kontrastmittel
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US5650135A (en) 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US5662885A (en) 1994-07-22 1997-09-02 Resolution Pharmaceuticals Inc. Peptide derived radionuclide chelators
GB9417941D0 (en) 1994-09-06 1994-10-26 Nycomed Imaging As Improvements in or relating to contrast agents
US5556939A (en) 1994-10-13 1996-09-17 Merck Frosst Canada, Inc. TC or RE radionuclide labelled chelate, hexapeptide complexes useful for diagnostic or therapeutic applications
US6221839B1 (en) 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
US6403088B1 (en) 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6245530B1 (en) 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US6333021B1 (en) 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
DE4445065A1 (de) 1994-12-07 1996-06-13 Diagnostikforschung Inst Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung
IL116328A (en) 1994-12-16 1999-09-22 Bracco Research Sa Frozen suspension of gas microbubbles in frozen aqueous carrier for use as contrast agent in ultrasonic imaging
TW319763B (fr) 1995-02-01 1997-11-11 Epix Medical Inc
GB9502065D0 (en) 1995-02-02 1995-03-22 Nycomed Imaging As Contrast media
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
EP0831932B1 (fr) 1995-06-07 2004-05-06 Imarx Pharmaceutical Corp. Nouvelles compositions ciblees, destinees a une utilisation diagnostique et therapeutique
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
EP0848755B2 (fr) 1995-09-08 2011-02-09 Genentech, Inc. Proteine apparentee au vegf
WO1997017442A1 (fr) 1995-11-08 1997-05-15 Immunex Corporation Proteine de liaison flk-1
US5837680A (en) 1996-02-16 1998-11-17 Children's Medical Center Corporation Pharmaceutical compositions comprising troponin subunits, fragments and analogs thereof and methods of their use to inhibit angiogenesis
CA2246779C (fr) 1996-02-19 2008-04-29 Nycomed Imaging A/S Perfectionnements relatifs aux milieux de contraste
ES2217408T3 (es) 1996-04-01 2004-11-01 Epix Medical, Inc. Agentes diagnosticos de contraste para formacion de imagenes bioactivados.
NZ334365A (en) 1996-08-02 1999-10-28 Nycomed Imaging As Use of a contrast agent comprising microbubbles of biocompatible gas stabilised by opsonisable amphiphilic material for ultrasound imaging of the liver
TW320761B (en) * 1996-10-03 1997-11-21 Mos Electronics Taiwan Inc Manufacturing method of high density DRAM with cylindrical stack capacitor
HU224218B1 (hu) 1996-10-21 2005-06-28 Amersham Health As Továbbfejlesztett kontrasztanyagok
WO1998018501A2 (fr) 1996-10-28 1998-05-07 Marsden, John, Christopher Ameliorations apportees a des agents diagnostiques et/ou therapeutiques ou les concernant
GB9708265D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
DE69735354T2 (de) 1996-10-28 2006-11-30 Amersham Health As Verbesserungen an oder in verbindung mit diagnostischen/therapeutischen verbindungen
WO1998018497A2 (fr) 1996-10-28 1998-05-07 Nycomed Imaging As Agents de contraste
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
WO1998018498A2 (fr) 1996-10-28 1998-05-07 Marsden, John, Christopher Ameliorations apportees a des agents diagnostiques et/ou therapeutiques ou les concernant
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
WO1998018496A2 (fr) 1996-10-28 1998-05-07 Nycomed Imaging As Agents de contraste
EP0991427A2 (fr) 1996-10-28 2000-04-12 Marsden, John Christopher Ameliorations apportees a des agents diagnostiques et/ou therapeutiques ou les concernant
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US5919967A (en) 1997-04-11 1999-07-06 Epix Medical, Inc. Process for synthesizing phosphodiesters
DE19717904A1 (de) 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
US6245318B1 (en) 1997-05-27 2001-06-12 Mallinckrodt Inc. Selectively binding ultrasound contrast agents
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
GB9712525D0 (en) 1997-06-16 1997-08-20 Nycomed Imaging As Method
WO1998058053A1 (fr) 1997-06-18 1998-12-23 Merck & Co., Inc. Tyrosine kinase receptrice, kdr
DE69819925T2 (de) 1997-10-02 2004-09-02 Epix Medical, Inc., Cambridge Kontrastverstärktes Diagnosebildererzeugungsverfahren zur Überwachung von therapeutischen Eingriffen
JP4312955B2 (ja) 1997-12-09 2009-08-12 チルドレンズ・メディカル・センター・コーポレイション 血管内皮増殖因子のペプチドアンタゴニスト
US6165458A (en) 1997-12-26 2000-12-26 Pharmaderm Laboratories Ltd. Composition and method for dermal and transdermal administration of a cytokine
EP1056473B8 (fr) 1998-02-09 2005-07-20 Bracco International B.V. Apport cible de milieux biologiquement actifs
EP1056773A2 (fr) 1998-02-11 2000-12-06 Resolution Pharmaceuticals Inc. Molecules ciblant l'angiogenese
US20020136721A1 (en) * 1998-02-17 2002-09-26 Schwall Ralph H. Hepatocyte growth factor receptor antagonists and uses thereof
SK13952000A3 (sk) 1998-03-31 2001-12-03 Dupont Pharmaceuticals Company Farmaceutické zlúčeniny na zobrazovanie porúch angiogenézy
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
TR200102278T2 (tr) 1998-11-06 2001-12-21 Basf Aktiengesellschaft Vasküler hiperpermeabilite oluşumunun önlenmesi.
US6312665B1 (en) 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
EP1169344A1 (fr) * 1999-03-12 2002-01-09 Human Genome Sciences, Inc. 47 proteines humaines secretees
JP2002542766A (ja) * 1999-03-12 2002-12-17 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５０個のヒト分泌タンパク質
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US6294525B1 (en) 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
GB9928950D0 (en) 1999-12-07 2000-02-02 Metris Therapeutics Limited Binding protein
EP1248642A4 (fr) 2000-01-18 2005-05-18 Ludwig Inst Cancer Res Inhibiteur peptidomimetique de vegf-d/vegf-c/vegf
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
JP2003528824A (ja) 2000-02-04 2003-09-30 スプラテック ファーマ インコーポレイティド 血管内皮成長因子受容体のためのリガンド
CA2400948A1 (fr) 2000-02-25 2001-08-30 Ludwig Institute For Cancer Research Materiaux et procedes impliquant un hybride d'adn de facteur de croissance de l'endothelium vasculaire et de proteines
PT1259248E (pt) 2000-03-02 2005-04-29 Ludwig Inst Cancer Res Metodos para tratar, rastrear e detectar cancros que expressam o factor de crescimento vascular endotelial d
US20020102260A1 (en) 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
US6769080B2 (en) * 2000-03-09 2004-07-27 Texas Instruments Incorporated Scan circuit low power adapter with counter
AU2001249393A1 (en) 2000-03-22 2001-10-03 Glaxo Group Limited Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
US20010031485A1 (en) 2000-03-22 2001-10-18 Sibtech, Inc. Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments
CA2404528A1 (fr) 2000-03-31 2001-10-04 Institut Pasteur Peptides inhibant l'angiogenese induite par le vegf (facteur de croissance endotheliale), polynucleotides codant pour ces peptides et leurs procedes d'utilisation
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001259195A1 (en) 2000-04-28 2001-11-12 Glaxo Group Limited Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses
US6689352B2 (en) 2000-05-03 2004-02-10 Ludwig Institute For Cancer Research Method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
KR100457350B1 (ko) * 2000-06-01 2004-11-16 이경림 ＩｇＥ-의존적 히스타민 방출인자(ＨＲＦ)의 수용체,ＨＲＦ 결합 펩타이드 및 그들을 코딩하는 핵산, 및그들의 용도
EP1166798A1 (fr) 2000-06-23 2002-01-02 Schering Aktiengesellschaft Combinaisons interférant avec la fonction des récepteurs VEGF/VEGF et angiopoietine/Tie
EP1166799A1 (fr) 2000-06-28 2002-01-02 Schering Aktiengesellschaft Combinaisons interférant avec la fonction des récepteurs VEGF/VEGF et angiopoietine/Tie
IL152794A0 (en) 2000-06-23 2003-06-24 Schering Ag Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use
EP1311277A4 (fr) 2000-07-18 2004-08-25 Joslin Diabetes Center Inc Procede de modulation de fibrose
US20020091082A1 (en) 2000-09-13 2002-07-11 Aiello Lloyd P. Methods of modulating symptoms of hypertension
FR2814744B1 (fr) 2000-10-04 2002-11-29 Commissariat Energie Atomique Cyclopeptides, leur procede de preparation et leur utilisation comme inhibiteur ou activateur de l'angiogenese
US20030082103A1 (en) 2000-10-11 2003-05-01 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
JP4669984B2 (ja) 2001-01-19 2011-04-13 ベジェニクス リミテッド 腫瘍画像化のターゲットとしてのＦ１ｔ４（ＶＥＧＦＲ−３）および抗腫瘍療法
WO2002083849A2 (fr) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Facteur de croissance endothélial vasculaire 2
WO2003000842A2 (fr) * 2001-06-04 2003-01-03 Curagen Corporation Nouvelles proteines et acides nucleiques codant pour de telles proteines
AU2002318356A1 (en) * 2001-06-22 2003-01-08 Incyte Genomics, Inc. Protein modification and maintenance molecules
WO2003028643A2 (fr) 2001-10-01 2003-04-10 Targesome, Inc. Structures lipidiques therapeutiques cibles comprenant des cibles en surface de cellules
US6766860B2 (en) * 2002-02-22 2004-07-27 Globalsantafe Corporation Multi-activity offshore drilling facility having a support for tubular string
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
EP1501357A4 (fr) 2002-05-06 2009-10-21 Genentech Inc Utilisation de vegf pour traiter des defauts osseux
DK2949658T3 (en) * 2003-03-03 2018-10-01 Dyax Corp Peptides that specifically bind HGF receptor (cMet) and uses thereof
ES2428964T3 (es) * 2005-12-09 2013-11-12 Bracco Suisse Sa Conjugados de vectores específicos de una diana-fosfolípidos
NZ587420A (en) * 2008-02-25 2012-07-27 Prometheus Lab Inc Drug selection for breast cancer therapy using antibody-based arrays
US9801473B2 (en) 2012-09-13 2017-10-31 Kids Ii, Inc. Play yard with removable liner
US9820182B2 (en) 2013-07-12 2017-11-14 Telefonaktiebolaget Lm Ericsson (Publ) Method for enabling control of data packet flows belonging to different access technologies

Also Published As

Publication number Publication date
US20150218218A1 (en) 2015-08-06
EP1944312A1 (fr) 2008-07-16
JP2017019787A (ja) 2017-01-26
JP6216280B2 (ja) 2017-10-18
US20110311446A1 (en) 2011-12-22
PL2949658T3 (pl) 2018-11-30
JP2007524598A (ja) 2007-08-30
DK2949658T3 (en) 2018-10-01
EP2284180A2 (fr) 2011-02-16
US20100261875A1 (en) 2010-10-14
PT2949658T (pt) 2018-10-18
CA2517939C (fr) 2015-11-24
US8044175B2 (en) 2011-10-25
EP2949658A2 (fr) 2015-12-02
AU2010235865A1 (en) 2010-11-11
PL1944312T3 (pl) 2012-12-31
AU2004217894B2 (en) 2010-07-15
DK2284180T3 (en) 2015-12-21
ES2557286T3 (es) 2016-01-25
JP2011037872A (ja) 2011-02-24
CA2517939A1 (fr) 2004-09-16
AU2004217894A1 (en) 2004-09-16
EP1603935A2 (fr) 2005-12-14
US9845340B2 (en) 2017-12-19
SI2949658T1 (sl) 2018-10-30
JP5466350B2 (ja) 2014-04-09
ES2396368T3 (es) 2013-02-21
US9000124B2 (en) 2015-04-07
EP2284180A3 (fr) 2011-10-05
ES2692166T3 (es) 2018-11-30
EP2949658B1 (fr) 2018-08-08
WO2004078778A3 (fr) 2004-11-18
US20120039802A1 (en) 2012-02-16
AU2010235865B2 (en) 2012-11-15
US20050214859A1 (en) 2005-09-29
US20100260672A1 (en) 2010-10-14
HUE039154T2 (hu) 2018-12-28
WO2004078778A2 (fr) 2004-09-16
JP5876644B2 (ja) 2016-03-02
JP6374913B2 (ja) 2018-08-15
CY1120683T1 (el) 2019-12-11
EP2284180B1 (fr) 2015-09-09
EP2949658A3 (fr) 2016-01-13
JP2014159434A (ja) 2014-09-04
EP1603935A4 (fr) 2007-03-21

Similar Documents

Publication Publication Date Title
EP1944312B1 (fr) Peptides qui lient spécifiquement le récepteur HGF (CMET) et utilisations associées
US7666979B2 (en) Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
JP5039075B2 (ja) Ｋｄｒおよびｖｅｇｆ／ｋｄｒ結合ペプチドならびに診断および治療におけるその使用
US20070243139A1 (en) Multivalent constructs for therapeutic and diagnostic applications
CA2477935C (fr) Produits de synthese multivalents pour applications therapeutiques et diagnostiques
AU2012241087B2 (en) Peptides that specifically bind HGF receptor (cMet) and uses thereof
AU2015201413B2 (en) Peptides that specifically bind HGF receptor (cMet) and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080428

AC Divisional application: reference to earlier application

Ref document number: 1603935

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20090130

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DYAX CORPORATION

Owner name: BRACCO SUISSE SA

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LADNER, ROBERT C.

Inventor name: NANJAPPAN, PALANIAPPA

Inventor name: SATO, AARON K.

Inventor name: DRANSFIELD, DANIEL T.

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 1603935

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 564186

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602004038394

Country of ref document: DE

Effective date: 20120823

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120627

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120627

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 564186

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120627

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120928

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120627

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120627

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120627

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120627

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120627

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120627

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120627

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120627

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2396368

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20130221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121029

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120627

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20130328

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602004038394

Country of ref document: DE

Effective date: 20130328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120927

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E016250

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130303

REG Reference to a national code

Ref country code: PL

Ref legal event code: LAPE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120627

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130303

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Effective date: 20210802

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004038394

Country of ref document: DE

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED, OSAKA-S, JP

Free format text: FORMER OWNERS: BRACCO SUISSE SA, CADEMPINO, CH; DYAX CORP., CAMBRIDGE, MASS., US

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004038394

Country of ref document: DE

Owner name: BRACCO SUISSE SA, CH

Free format text: FORMER OWNERS: BRACCO SUISSE SA, CADEMPINO, CH; DYAX CORP., CAMBRIDGE, MASS., US

REG Reference to a national code

Ref country code: NL

Ref legal event code: PD

Owner name: BRACCO SUISSE SA; CH

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: DYAX CORPORATION

Effective date: 20211105

REG Reference to a national code

Ref country code: HU

Ref legal event code: GB9C

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED, JP

Free format text: FORMER OWNER(S): DYAX CORPORATION, US; BRACCO SUISSE SA, CH

Ref country code: HU

Ref legal event code: GB9C

Owner name: BRACCO SUISSE SA, CH

Free format text: FORMER OWNER(S): DYAX CORPORATION, US; BRACCO SUISSE SA, CH

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20220324 AND 20220330

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230221

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20230222

Year of fee payment: 20

Ref country code: FR

Payment date: 20230222

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230221

Year of fee payment: 20

Ref country code: HU

Payment date: 20230301

Year of fee payment: 20

Ref country code: GB

Payment date: 20230221

Year of fee payment: 20

Ref country code: DE

Payment date: 20230221

Year of fee payment: 20

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230530

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20230403

Year of fee payment: 20

Ref country code: CH

Payment date: 20230401

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 602004038394

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20240302

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20240326

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20240302

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240304

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240304

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240302

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240303

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240303